0001079973-22-000358 | 10-K | XBRL Viewer

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 36,080,392	$ 13,360,463
Accounts receivable, net	1,172,396	653,104
Inventory, net	1,239,456	1,485,986
Prepaid expenses and other current assets	1,250,331	1,388,090
Total current assets	39,742,575	16,887,643
Property and equipment, net	4,011,748	3,259,487
Finance lease right-of-use assets, net	90,467	449,628
Operating lease right-of-use assets	1,814,396	2,082,300
Goodwill	7,453,007	8,024,729
Intangible assets, net	14,530,209	16,580,963
Strategic inventory	3,472,337	1,686,342
Other noncurrent assets	551,794	779,953
Total assets	71,666,533	49,751,045
Current liabilities
Accounts payable	1,307,081	1,868,666
Accrued compensation and benefits	1,621,788	2,126,511
Accrued liabilities	1,965,845	1,437,141
Deferred revenue		9,808
Short-term notes payable	14,519,113	699,000
Short-term finance lease liabilities	43,150	266,470
Short-term operating lease liabilities	459,792	964,434
Total current liabilities	19,916,769	7,372,030
Note payable	7,176,251	19,378,935
Derivative liabilities	228,589	112,852
Long-term finance lease liabilities	3,644	46,794
Long-term operating lease liabilities	2,977,402	1,492,544
Other long-term liabilities	146,798	156,635
Total liabilities	30,449,453	28,559,790
Commitments and Contingencies (Note 10)
Stockholders' equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at December 31, 2021 and 2020, respectively
Common stock, $0.01 par value; 100,000,000 shares authorized; 46,450,250 and 25,085,534 shares issued and outstanding at December 31, 2021 and 2020, respectively	464,503	250,855
Additional paid-in capital	275,708,490	219,129,045
Accumulated deficit	(235,541,539)	(200,735,827)
Accumulated other comprehensive income	585,626	2,547,182
Total stockholders' equity	41,217,080	21,191,255
Total liabilities and stockholders' equity	$ 71,666,533	$ 49,751,045

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 08, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01		$ 0.01
Preferred stock, shares authorized	10,000,000		10,000,000
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Common stock, par value (in dollars per share)	$ 0.01		$ 0.01
Common stock, shares authorized	100,000,000	100,000,000	50,000,000
Common stock, shares issued	46,450,250		25,085,534
Common stock, shares outstanding	46,450,250		25,085,534

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue
Total revenue	$ 4,306,031	$ 4,214,441
Operating expenses
Research and development, net	10,910,679	9,964,720
General and administrative	9,935,963	8,801,661
Sales and marketing	3,713,263	3,094,092
Transaction costs		471,522
Impairment of right-of-use asset	170,714	101,838
Impairment of intangible assets		750,596
Gain on sale of equipment		(100,000)
Total operating expenses	27,579,067	26,932,920
Operating loss	(23,273,036)	(22,718,479)
Other expense
Gain on extinguishment of debt	259,353	884,970
Warrant inducement expense	(7,755,541)
Interest and other income, net	45,179	105,627
Interest expense	(4,799,331)	(3,399,384)
Foreign currency transaction gains/(losses)	891,223	(1,468,855)
Change in fair value of derivative financial instruments	(129,731)	517,680
Total other expense	(11,488,848)	(3,359,962)
Loss before income taxes	(34,761,884)	(26,078,441)
Provision for income taxes	43,828	132,403
Net loss	(34,805,712)	(26,210,844)
Deemed dividend on beneficial conversion feature	(7,166,752)
Net loss available to common stockholders	$ (41,972,464)	$ (26,210,844)
Basic and diluted net loss per share attributable to common stockholders	$ (1.14)	$ (1.66)
Weighted average shares outstanding - basic and diluted	36,674,083	15,800,781
Net loss	$ (34,805,712)	$ (26,210,844)
Other comprehensive (loss) income - foreign currency translation	(1,961,556)	2,564,497
Comprehensive loss	(36,767,268)	(23,646,347)
Product sales [Member]
Revenue
Total revenue	2,656,669	2,704,364
Operating expenses
Cost of products and services	2,295,828	3,360,280
Laboratory services [Member]
Revenue
Total revenue	813,210	167,736
Operating expenses
Cost of products and services	552,620	488,211
Collaborations Revenue [Member]
Revenue
Total revenue	$ 836,152	$ 1,342,341

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2019	$ 55,823		$ 178,779,814	$ (17,315)	$ (174,524,983)	$ 4,293,339
Balance (in shares) at Dec. 31, 2019	5,582,280
Offering of common stock and warrants, net of issuance costs	$ 48,426		9,240,703			9,289,129
Offering of common stock and warrants, net of issuance costs (in shares)	4,842,615
Beneficial conversion option on convertible preferred stock
Deemed dividend on beneficial conversion feature
At the market offering, net of offering costs	$ 75,216		15,746,706			15,821,922
At the market offering, net of offering costs (in shares)	7,521,610
Warrant exercises	$ 43,410		8,638,590			8,682,000
Warrant exercises (in shares)	4,341,000
Issuance of RSUs	$ 59		(59)
Issuance of RSUs (in shares)	5,916
Stock compensation expense			316,086			316,086
Shares issued to settle convertible notes	$ 7,639		1,443,158			1,450,797
Shares issued to settle convertible notes (in shares)	763,905
Shares issued in business combination	$ 20,282		4,827,135			4,847,417
Shares issued in business combination (in shares)	2,028,208
Value of equity awards assumed in business combination			136,912			136,912
Foreign currency translation				2,564,497		2,564,497
Net loss					(26,210,844)	(26,210,844)
Balance at Dec. 31, 2020	$ 250,855		219,129,045	2,547,182	(200,735,827)	21,191,255
Balance (in shares) at Dec. 31, 2020	25,085,534
Offering of common stock and warrants, net of issuance costs	$ 83,334		23,390,628			23,473,962
Offering of common stock and warrants, net of issuance costs (in shares)	8,333,333
Offering of preferred stock and warrants, net of issuance costs		$ 1,500	13,849,759			13,851,259
Offering of preferred stock and warrants, net of issuance costs, shares		150,000
Conversion of preferred stock into common stock	$ 75,000	$ (1,500)	(73,500)
Conversion of preferred stock into common stock, shares	7,500,000	(150,000)
Beneficial conversion option on convertible preferred stock			7,166,752			7,166,752
Deemed dividend on beneficial conversion feature			(7,166,752)			(7,166,752)
At the market offering, net of offering costs	$ 6,800		1,477,033			1,483,833
At the market offering, net of offering costs (in shares)	680,000
Warrant exercises	$ 48,476		9,045,696			9,094,172
Warrant exercises (in shares)	4,847,615
Proceeds from the issuance of warrants			255,751			255,751
Warrant inducement			7,755,541			7,755,541
Issuance of RSUs	$ 38		(38)
Issuance of RSUs (in shares)	3,768
Stock compensation expense			878,575			878,575
Shares issued in business combination
Foreign currency translation				(1,961,556)		(1,961,556)
Net loss					(34,805,712)	(34,805,712)
Balance at Dec. 31, 2021	$ 464,503		$ 275,708,490	$ 585,626	$ (235,541,539)	$ 41,217,080
Balance (in shares) at Dec. 31, 2021	46,450,250

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (34,805,712)	$ (26,210,844)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	2,713,907	2,334,739
Noncash interest expense	3,988,755	2,632,241
Noncash interest income		(87,233)
Stock compensation expense	878,575	316,086
Gain on sale of equipment		(100,000)
Gain on extinguishment of debt	(259,353)	(884,970)
Warrant inducement expense	7,755,541
Change in fair value of derivative financial instruments	129,731	(517,680)
Impairment of right-of-use asset	170,714	101,838
Impairment of intangible assets		750,596
Changes in operating assets and liabilities, net of acquisition
Accounts receivable	(575,123)	438,284
Inventory	(2,336,714)	(410,341)
Other assets	739,429	1,152,200
Accounts payable	(471,824)	(481,453)
Accrued compensation and other liabilities	602,605	(1,559,881)
Deferred revenue	(9,808)	(870,114)
Net cash used in operating activities	(21,479,277)	(23,396,532)
Cash flows from investing activities
Acquisition of business net of cash acquired		1,266,849
Note receivable		(2,200,000)
Purchases of property and equipment	(1,983,614)	(130,354)
Net cash used in investing activities	(1,983,614)	(1,063,505)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	1,483,833	15,821,922
Proceeds from issuance of common stock warrants	255,751
Proceeds from issuance of common stock and pre-funded warrants in private placement, net of selling costs		9,289,129
Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of selling costs	23,473,962
Proceeds from the exercise of common warrants	9,094,172	8,682,000
Proceeds from issuance of preferred stock and warrants, net of issuance costs	13,851,259
Proceeds from debt, net of issuance costs		1,871,308
Payments on debt	(441,076)	(998,182)
Payments on finance lease obligations	(266,470)	(579,029)
Net cash provided by financing activities	47,451,431	34,087,148
Effects of exchange rates on cash	(1,463,609)	1,586,541
Net increase in cash, cash equivalents and restricted cash	22,524,931	11,213,652
Cash and cash equivalents and restricted cash at beginning of year	14,107,255	2,893,603
Cash and cash equivalents and restricted cash at end of year	36,632,186	14,107,255
Supplemental disclosure of cash flow information
Cash paid for interest	895,200	952,050
Supplemental disclosures of noncash investing and financing activities
Right-of-use assets acquired through operating leases	615,761	1,008,039
Deemed dividend - beneficial conversion option on preferred stock	7,166,752
Inventory transferred to property and equipment	530,638
Shares issued in business combination		4,847,417
Shares issued to settle convertible notes		1,450,797
Note receivable from sale of equipment included in other assets		$ 100,000

Organization

12 Months Ended

Dec. 31, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Note 1 - Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. On April 1, 2020, OpGen completed its business combination transaction (the “Transaction”) with Curetis N.V., a public company with limited liability under the laws of the Netherlands (the “Seller” or “Curetis N.V.”), as contemplated by the Implementation Agreement, dated as of September 4, 2019 (the “Implementation Agreement”), by and among the Company, the Seller, and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly-owned subsidiary of the Company (the “Purchaser”). Pursuant to the Implementation Agreement, the Purchaser acquired all of the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany (“Curetis GmbH”), and certain other assets and liabilities of the Seller (together, “Curetis”) (see Note 4). References to the “Company” include OpGen and its wholly-owned subsidiaries. The Company’s headquarters are in Rockville, Maryland and the Company’s principal operations are in Rockville, Maryland; Holzgerlingen and Bodelshausen, Germany; and Vienna, Austria. The Company operates in one business segment.

OpGen Overview

OpGen is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Our current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.

Following its initial announcement in October 2020, the Company discontinued its QuickFISH and PNA FISH product portfolio in its entirety during the first quarter of 2021 (see Note 12). The Company's FISH customers and distribution partners have been informed accordingly and last orders were received and processed in the first quarter of 2021. The discontinuance of these product lines did not qualify for discontinued operations reporting.

The focus of OpGen is on its combined broad portfolio of products, which include high impact rapid diagnostics and bioinformatics to interpret Antimicrobial resistance (AMR) genetic data. OpGen will continue to develop and seek FDA and other regulatory clearances or approvals, as applicable, for the Unyvero UTI and IJI products. OpGen will continue to offer the FDA-cleared Unyvero LRT and LRT BAL Panels, Acuitas AMR Gene Panel diagnostic test, as well as the Unyvero UTI Panel as a RUO product to hospitals, public health departments, clinical laboratories, pharmaceutical companies and contract research organizations, or CROs. OpGen will also continue to commercialize its CE Marked Unyvero Panels in Europe and other global markets via distributors.

Going Concern and Management's Plans

12 Months Ended

Dec. 31, 2021

Liquidation Basis Of Accounting Abstract [Abstract]

Going Concern and Management's Plans

Note 2 - Going Concern and Management’s Plans

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations and negative operating cash flows and has a significant amount of debt coming due in 2022. The Company has funded its operations primarily through external investor financing arrangements and significant actions taken by the Company, including the following:

•

On October 18, 2021, the Company closed a registered direct offering (the “October 2021 Offering”) with a single healthcare-focused institutional investor of 150,000 shares of convertible preferred stock and warrants to purchase up to an aggregate of 7,500,000 shares of common stock. The shares of preferred stock had a stated value of $100 per share and were converted into an aggregate of 7,500,000 shares of common stock at a conversion price of $2.00 per share after the Company received stockholder approval for an increase to its number of authorized shares of common stock, which approval occurred at the Company’s special meeting of stockholders held in December 2021. Thereafter, all preferred stock was converted into 7,500,000 common shares in December 2021 so that there were no shares of preferred stock outstanding as of December 31, 2021. The warrants have an exercise price of $2.05 per share, will become exercisable six months following the date of issuance, and will expire five years following the initial exercise date. The October 2021 Offering raised aggregate net proceeds of $13.9 million, and gross proceeds of $15.0 million.

F-9

•

On March 9, 2021, the Company entered into a Warrant Exercise Agreement (the “Exercise Agreement”) with the institutional investor (the “Holder”) from our 2020 PIPE financing (see discussion below for a description of the 2020 PIPE). Pursuant to the Exercise Agreement, in order to induce the Holder to exercise all of the remaining 4,842,615 outstanding warrants acquired in the 2020 PIPE (the “Existing Warrants”) for cash, pursuant to the terms of and subject to beneficial ownership limitations contained in the Existing Warrants, the Company agreed to issue to the Holder new warrants (the “New Warrants”) to purchase 0.65 shares of common stock for each share of common stock issued upon such exercise of the Existing Warrants pursuant to the Exercise Agreement for an aggregate of 3,147,700 New Warrants. The terms of the New Warrants are substantially similar to those of the Existing Warrants, except that the New Warrants have an exercise price of $3.56. The New Warrants are immediately exercisable and will expire five years from the date of the Exercise Agreement. The Holder paid an aggregate of $255,751 to the Company for the purchase of the New Warrants. The Company received aggregate gross proceeds before expenses of approximately $9.65 million from the exercise of the remaining Existing Warrants held by the Holder and the payment of the purchase price for the New Warrants (together, the “2021 Warrant Exercise”). As additional compensation, A.G.P./Alliance Global Partners, the Company’s placement agent for such warrant exchange, will receive a cash fee equal to $200,000 upon the cash exercise in full of the New Warrants.

•

On February 11, 2021, the Company closed a registered direct offering (the "February 2021 Offering”) with a single U.S.-based, healthcare-focused institutional investor for the purchase of (i) 2,784,184 shares of common stock and (ii) 5,549,149 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock. The Company also issued to the investor, in a concurrent private placement, unregistered common share purchase warrants to purchase 4,166,666 shares of the Company's common stock. Each share of common stock and accompanying common warrant were sold together at a combined offering price of $3.00, and each pre-funded warrant and accompanying common warrant were sold together at a combined offering price of $2.99. The pre-funded warrants were immediately exercisable, at an exercise price of $0.01, and could be exercised at any time until all of the pre-funded warrants are exercised in full. The common warrants have an exercise price of $3.55 per share, are exercisable commencing on the six-month anniversary of the date of issuance, and will expire five and one-half (5.5) years from the date of issuance. The February 2021 Offering raised aggregate net proceeds of $23.5 million, and gross proceeds of $25.0 million. As of December 31, 2021, all 5,549,149 pre-funded warrants issued in the February 2021 Offering have been exercised.

•

On November 25, 2020, the Company closed a private placement (the “2020 PIPE”) with one healthcare-focused U.S. institutional investor for the purchase of (i) 2,245,400 shares of common stock, (ii) 4,842,615 warrants to purchase shares of common stock and (iii) 2,597,215 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock. Each share of common stock and accompanying common warrant were sold together at a combined offering price of $2.065, and each pre-funded warrant and accompanying common warrant were sold together at a combined offering price of $2.055. The common warrants have an exercise price of $1.94 per share, and are exercisable commencing on the six-month anniversary of the date of issuance, and will expire five and one-half (5.5) years from the date of issuance. The 2020 PIPE raised aggregate net proceeds of $9.3 million, and gross proceeds of $10.0 million. As of December 31, 2020, all 2,597,215 pre-funded warrants issued in the 2020 PIPE were exercised.

•

On February 11, 2020, the Company entered into an At the Market Common Offering (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), which was amended and restated on November 13, 2020 to add BTIG, LLC (“BTIG”), pursuant to which the Company may offer and sell from time to time in an “at the market offering”, at its option, up to an aggregate of $22.1 million of shares of the Company's common stock through the sales agents (the “2020 ATM Offering”). During the year ended December 31, 2020, the Company sold 7,521,610 shares of its common stock under the 2020 ATM Offering resulting in aggregate net proceeds to the Company of approximately $15.8 million, and gross proceeds of $16.7 million. During the year ended December 31, 2021, the Company sold 680,000 shares of its common stock under the 2020 ATM Offering, resulting in aggregate net proceeds to the Company of approximately $1.48 million, and gross proceeds of approximately $1.55 million.

F-10

To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, strategic financings or other transactions, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash, will be sufficient to repay or refinance the current portion of the Company’s debt and fund operations into the fourth quarter of 2022. This has led management to conclude that there is substantial doubt about the Company’s ability to continue as a going concern. In the event the Company is unable to successfully raise additional capital during or before the end of the fourth quarter of 2022, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances, the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, pause or abort clinical trials including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing. If such sufficient financing is not received on a timely basis, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 - Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements consolidate the operations of all controlled subsidiaries; all intercompany activity is eliminated.

Foreign Currency

The Company has subsidiaries located in Holzgerlingen, Germany; Vienna, Austria; and Copenhagen, Denmark, each of which use currencies other than the U.S. dollar as their functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive income (loss), a component of stockholders’ equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive income (loss) at December 31, 2021 and 2020.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss. Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of Estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, inducement expense related to warrant repricing, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, deferred tax assets and liabilities and related valuation allowance, determining the fair value of assets acquired and liabilities assumed in business combinations, the estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

Financial instruments classified as current assets and liabilities (including cash and cash equivalent, receivables, accounts payable, deferred revenue and short-term notes) are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.

For additional fair value disclosures, see Note 6.

Cash and cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the Federal Deposit Insurance Corporation (“FDIC”) insured limit of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

F-11

At December 31, 2021 and 2020, the Company had funds totaling $551,794 and $746,792, respectively, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying consolidated balance sheets.

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:

	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	36,080,392	$	13,360,463
Restricted cash		551,794		746,792
Total cash and cash equivalents and restricted cash in the consolidated statements of cash flows	$	36,632,186	$	14,107,255

Accounts receivable

The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $0 and $20,753 as of December 31, 2021 and 2020, respectively.

At December 31, 2021, the Company had accounts receivable from two customers which individually represented 52% and 14% of total accounts receivable, respectively. At December 31, 2020, the Company had accounts receivable from one customer which individually represented 20% of total accounts receivable. For the year ended December 31, 2021, revenue earned from three customers represented 15%, 13%, and 12% of total revenues, respectively. For the year ended December 31, 2020, revenue earned from one customer represented 21% of total revenues.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	December 31,
	2021		2020
Raw materials and supplies	$	866,963	$	773,021
Work-in-process		100,801		87,159
Finished goods		3,744,029		2,312,148
Total	$	4,711,793	$	3,172,328

Inventory includes Unyvero instrument systems, Unyvero cartridges, reagents and components for Unyvero, Acuitas, Curetis SARS CoV-2 test kits, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $98,064 and $288,378 at December 31, 2021 and 2020, respectively.

The Company reviews inventory quantities on hand and analyzes the provision for excess and obsolete inventory based primarily on product expiration dating and its estimated sales forecast, which is based on sales history and anticipated future demand. The Company’s estimates of future product demand may not be accurate, and it may understate or overstate the provision required for excess and obsolete inventory. Accordingly, any significant unanticipated changes in demand could have a significant impact on the value of the Company’s inventory and results of operations.

The Company classifies finished good inventory it does not expect to sell or use in clinical studies within 12 months of the consolidated balance sheets date as strategic inventory, a non-current asset.

F-12

Long-lived assets

Property and equipment

Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets. The estimated service lives range from three to ten years. Depreciation expense was $1,541,561 and $1,152,954 for the years ended December 31, 2021 and 2020, respectively. Property and equipment consisted of the following at December 31, 2021 and 2020:

	December 31,
	2021			2020
Laboratory and manufacturing equipment	$	4,613,324		$	6,317,340
Office furniture and equipment		810,574			1,259,838
Computers and network equipment		491,183			1,692,154
Leasehold improvements		1,634,692			752,493
		7,549,773			10,021,825
Less accumulated depreciation		(3,538,025	)		(6,762,338	)
Property and equipment, net	$	4,011,748		$	3,259,487

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the years ended December 31, 2021 and 2020, the Company determined that its property and equipment was not impaired.

Leases

The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, right-of-use (“ROU”) assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.

Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method of recognition. The Company has made certain accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases.

ROU Assets

ROU assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which the Company can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the year ended December 31, 2021, the Company determined that the ROU asset associated with its San Diego, California office lease may not be recoverable. As a result, during the year ended December 31, 2021, the Company recorded an impairment charge of $170,714. The Company also recorded an impairment charge of $101,838 during the year ended December 31, 2020 related to its ROU asset associated with its Woburn, Massachusetts office lease.

F-13

Intangible assets and goodwill

Intangible assets and goodwill as of December 31, 2021 consist of finite-lived and indefinite-lived intangible assets and goodwill.

Finite-lived and indefinite-lived intangible assets

Intangible assets include trademarks, developed technology, In-Process Research & Development, software and customer relationships and consisted of the following as of December 31, 2021 and 2020:

					December 31, 2021							December 31, 2020
	Subsidiary		Cost		Accumulated Amortization and Prior Year Impairment			Effect of Foreign Exchange Rates		Net Balance		Accumulated Amortization			Impairment			Effect of Foreign Exchange Rates		Net Balance
Trademarks and tradenames		AdvanDx	$	461,000	$	(461,000	)	$	—	$	—	$	(217,413	)	$	(243,587	)	$	—	$	—
Developed technology		AdvanDx		458,000		(458,000	)		—		—		(308,526	)		(149,474	)		—		—
Customer relationships		AdvanDx		1,094,000		(1,094,000	)		—		—		(736,465	)		(357,535	)		—		—
Trademarks and tradenames		Curetis		1,768,000		(316,930	)		43,015		1,494,085		(147,161	)		—			194,119		1,814,958
Distributor relationships		Curetis		2,362,000		(282,277	)		57,465		2,137,188		(131,070	)		—			259,336		2,490,266
A50 - Developed technology		Curetis		349,000		(89,384	)		8,492		268,108		(41,504	)		—			38,319		345,815
Ares - Developed technology		Curetis		5,333,000		(682,833	)		129,745		4,779,912		(317,060	)		—			585,536		5,601,476
A30 - In-Process Research & Development		Curetis		5,706,000		—			144,916		5,850,916		—			—			622,448		6,328,448
			$	17,531,000	$	(3,384,424	)	$	383,633	$	14,530,209	$	(1,899,199	)	$	(750,596	)	$	1,699,758	$	16,580,963

Identifiable intangible assets will be amortized on a straight-line basis over their estimated useful lives. The estimated useful lives of the intangibles are:

		Estimated Useful Life
Trademarks and tradenames		10 years
Customer/distributor relationships		15 years
A50 – Developed technology		7 years
Ares – Developed technology		14 years
A30 – Acquired in-process research & development		Indefinite

Acquired IPR&D represents the fair value assigned to those research and development projects that were acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a finite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&D which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset’s carrying value over its fair value.

The Company reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.

F-14

Total amortization expense of intangible assets was $813,184 and $672,823 for the years ended December 31, 2021 and 2020, respectively. Expected future amortization of intangible assets is as follows:

Year Ending December 31,
2022	$	783,669
2023		783,669
2024		783,669
2025		783,669
2026		783,669
Thereafter		4,760,948
Total	$	8,679,293

Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any.

In accordance with ASC 360-10, Property, Plant and Equipment, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. During the year ended December 31, 2020, events and circumstances indicated the Company’s FISH intangible assets might be impaired. These circumstances included decreased product sales related to the COVID-19 pandemic and the loss of significant customers. Management’s updated estimate of undiscounted cash flows indicated that such carrying amounts were no longer expected to be recovered and that the FISH intangible assets were impaired. The Company’s analysis determined that the fair value of the assets was $0 and the Company recorded an impairment loss of $750,596. During 2021, events and circumstances indicated the Company’s intangible assets might be impaired. However, management’s estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered. Nonetheless, it is reasonably possible that the estimate of undiscounted cash flows may change in the near term, resulting in the need to write down those assets to fair value.

Goodwill

Goodwill represents the excess of the purchase price paid when the Company acquired AdvanDx, Inc. in July 2015 and Curetis in April 2020, over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions. The Company’s goodwill balance as of December 31, 2021 and 2020 was $7,453,007 and $8,024,729, respectively.

The changes in the carrying amount of goodwill as of December 31, 2021, and since December 31, 2019, were as follows:

Balance as of December 31, 2019	$	600,814
Acquisition of Curetis		6,688,652
Changes in currency translation		735,263
Balance as of December 31, 2020		8,024,729
Changes in currency translation		(571,722	)
Balance as of December 31, 2021	$	7,453,007

The Company conducts an impairment test of goodwill on an annual basis, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value. During the years ended December 31, 2021 and 2020, the Company determined that its goodwill was not impaired.

Revenue recognition

The Company derives revenues from (i) the sale of Unyvero Application cartridges, Unyvero Systems, SARS CoV-2 tests, Acuitas AMR Gene Panel test products, (ii) providing laboratory services, (iii) providing collaboration services including funded software arrangements, and license arrangements, and (iv) granting access to a small subset of the proprietary ARESdb data asset.

F-15

The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers, (ii) identification of distinct performance obligations in the contract, (iii) determination of contract transaction price, (iv) allocation of contract transaction price to the performance obligations and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation.

The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to our customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.

The Company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The Company had no material incremental costs to obtain customer contracts in any period presented.

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

Government grant agreements and research incentives

From time to time, the Company may enter into arrangements with governmental entities for the purposes of obtaining funding for research and development activities. The Company recognizes funding from grants and research incentives received European government agencies in the consolidated statements of operations and comprehensive loss in the period during which the related qualifying expenses are incurred, provided that the conditions under which the grants or incentives were provided have been met. For grants under funding agreements and for proceeds under research incentive programs, the Company recognizes grant and incentive income in an amount equal to the estimated qualifying expenses incurred in each period multiplied by the applicable reimbursement percentage. The Company classifies government grants received under these arrangements as a reduction to the related research and development expense incurred. The Company analyzes each arrangement on a case-by-case basis. For the year ended December 31, 2021, the Company recognized $692,701 as a reduction of research and development expense related to government grant arrangements. For the year ended December 31, 2020, the Company recognized $495,153 as a reduction of research and development expense related to government grant arrangements. As of December 31, 2021 and 2020, the Company had earned but not yet received $396,365 and $413,530, respectively related to these agreements and incentives included in prepaid expenses and other current assets.

Research and development costs, net

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, development materials, fees paid to consultants and outside service partners.

Stock-based compensation

Stock-based compensation expense is recognized at fair value. The fair value of stock-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. A discussion of management’s methodology for developing each of the assumptions used in the Black-Scholes model is as follows:

Fair value of common stock

The Company uses the quoted market price of its common stock as its fair value.

F-16

Expected volatility

Through 2020, since OpGen did not have sufficient history to estimate the expected volatility of its common stock price, expected volatility was based on the volatility of peer public entities that were similar in size and industry. Beginning in 2021, for stock options with an expected term where there is sufficient history available, expected volatility is based on the volatility of OpGen's common stock.

Expected dividend yield

The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.

Risk-free interest rate

This is the U.S. Treasury rate for the day of each option grant during the year, having a term that most closely resembles the expected term of the option.

Expected term

This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected term of the option to be 6.25 years for options with a standard four-year vesting period, using the simplified method. Over time, management will track actual terms of the options and adjust their estimate accordingly so that estimates will approximate actual behavior for similar options.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss (“NOL”) carryforwards of $202,015,062 and $196,511,928 at December 31, 2021 and 2020, respectively. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

The Company also has foreign NOL carryforwards of $170,607,782 at December 31, 2021 from their foreign subsidiaries. $147,313,786 of those foreign NOL carryforwards are from the Company’s operations in Germany. Despite the NOL carryforwards, the Company may have a current and future tax liability due to the nuances of German tax law around the use of NOL’s within a consolidated group. There is no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

F-17

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) restricted stock units representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was 18.2 million shares and 7.5 million shares as of December 31, 2021 and 2020, respectively.

Adopted accounting pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which removes certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, the recognition of deferred tax liabilities for outside basis differences and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted ASU 2019-12 on January 1, 2021. The impact of adopting ASU 2019-12 did not have a material impact on the Company’s consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The new guidance under ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. The impact of adopting ASU 2020-04 did not have a material impact on the Company’s consolidated financial statements.

Recently issued accounting standards

The Company has evaluated all other issued and unadopted ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or cash flows.

Business Combination

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Business Combination

Note 4 - Business Combination

On April 1, 2020, the Company completed its business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands, as contemplated by the Implementation Agreement, dated as of September 4, 2019, by and among the Company, the Seller, and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly-owned subsidiary of the Company. Pursuant to the Implementation Agreement, the Purchaser acquired all of the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany, and certain other assets and liabilities of the Seller, as further described below, and paid, as the sole consideration, 2,028,208 shares of the Company’s common stock, to the Seller, and reserved for future issuance (a) 134,356 shares of common stock, in connection with its assumption of the Seller’s 2016 Stock Option Plan, as amended (the “Seller Stock Option Plan”), and the outstanding awards thereunder, and (b) 500,000 shares of common stock to be issued upon the conversion, if any, of certain convertible notes issued by the Seller.

At the closing, the Company assumed all of the liabilities of the Seller solely and exclusively related to the acquired business, which is providing innovative solutions, through development of proprietary platforms, diagnostic content, applied bioinformatics, lab services, research services and commercial collaborations and agreements, for molecular microbiology, diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients. Pursuant to the Implementation Agreement, the Company also assumed and adopted the Seller Stock Option Plan as an Amended and Restated Stock Option Plan of the Company. In connection with the foregoing, the Company assumed all awards thereunder that were outstanding as of the closing date and converted such awards into options to purchase shares of the Company’s common stock pursuant to the terms of the applicable award. In addition, the Company assumed, at the closing, all of the outstanding convertible notes issued by the Seller in favor of YA II PN, LTD, pursuant to the Assignment of the Agreement for the Issuance of and Subscription to Notes Convertible into Shares, dated February 24, 2020, and entered into pursuant to the Implementation Agreement.

F-18

Curetis’ assets and liabilities were measured and recognized at their fair values as of the transaction date and combined with the assets, liabilities and results of operations of OpGen after the consummation of the business combination. The allocation of the purchase price to acquired assets and assumed liabilities based on their underlying fair values requires the extensive use of significant estimates and management’s judgment.

The components of the purchase price and net assets acquired are as follows:

Purchase Price

Number of shares issued to Curetis N.V		2,028,208
Multiplied by the market value per share of OpGen's common stock (i)	$	2.39
Total fair value of common stock issued to Curetis N.V shareholders		4,847,417
Fair value of replacement stock awards related to precombination service (ii)		136,912
Fair value of convertible notes assumed (iii)		1,323,750
Fair value of EIB debt assumed (iv)		15,784,892
Funds advanced to Curetis GmbH under Interim Facility		4,808,712
Cash, cash equivalents, and restricted cash acquired		(1,266,849	)
	$	25,634,834

	(i)			The price per share of OpGen’s common stock was based on the closing price as reported on the Nasdaq Capital Market on April 1, 2020.
	(ii)			The fair value of the stock options assumed was determined using the Black-Scholes option pricing model.
	(iii)			To derive the fair value of the convertible notes, the Company estimated the fair value of the convertible notes with and without the derivative liability using a scenario analysis and Monte Carlo simulation.
	(iv)			The fair value of the EIB debt is determined using a discounted cash flow analysis with current applicable rates for similar instruments.

Net Assets Acquired

Assets acquired
Receivables	$	482,876
Inventory		2,022,577
Property and equipment		3,802,431
Right of use assets		1,090,812
Other current assets		925,364
Finite-lived intangible assets
Trade names/trademarks		1,768,000
Customer/distributor relationships		2,362,000
A50 - Developed technology		349,000
Ares - Developed technology		5,333,000
Indefinite-lived intangible assets
A30 - In-process research & development		5,706,000
Goodwill		6,688,652
Liabilities assumed
Accounts payable		(1,168,839	)
Accrued expenses and other current liabilities		(1,953,927	)
Derivative liabilities		(615,831	)
Lease liabilities		(1,108,193	)
Other long-term liabilities		(49,088	)
Net assets acquired	$	25,634,834

The fair value of identifiable intangible assets has been determined using the income approach, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, required rate of return and tax rate, as well as an estimated royalty rate in the case of the trade names/trademarks intangibles. The trade names/trademarks intangibles are valued using a relief-from-royalty method. The customer/distributor relationships are valued using the with and without method. The developed technology intangibles are valued using a multi-period earnings method.

F-19

The Company determined the fair value of an IPR&D asset resulting from the acquisition of Curetis using the multi-period earnings method under the income approach. This method reflects the present value of the projected cash flows that are expected to be generated by the IPR&D, less charges representing the required return on other assets to sustain those cash flows.

The weighted-average amortization periods for finite-lived intangible assets acquired are 15 years for customer/distributor relationships, 10 years for developed technology and 10 years for trade names/trademarks.

The total consideration paid in the acquisition exceeded the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in approximately $6.7 million of goodwill. Goodwill, primarily related to expected synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, is not tax deductible in all relevant taxing jurisdictions.

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Transaction had been completed as of January 1, 2020. Pro forma information primarily reflects adjustments relating to the amortization of intangibles acquired and elimination of interest expense due under the interim facility. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2020 or that may be obtained in the future.

Unaudited pro forma results	Year ended December 31,
	2020
Revenues	$	5,239,192
Net loss		(29,319,303	)
Net loss per share		(1.86	)

Revenue from Contracts with Customers

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Note 5 - Revenue from Contracts with Customers

Disaggregated Revenue

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

	Years Ended December,
	2021		2020
Product sales	$	2,656,669	$	2,704,364
Laboratory services		813,210		167,736
Collaboration revenue		836,152		1,342,341
Total revenue	$	4,306,031	$	4,214,441

Revenues by geography are as follows:

	Years Ended December,
	2021		2020
Domestic	$	1,203,748	$	1,917,367
International		3,102,283		2,297,074
Total revenue	$	4,306,031	$	4,214,441

F-20

Deferred revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2019	$	9,808
Acquired deferrals from Curetis		829,275
Revenue recognized in the period from amounts acquired from Curetis		(870,114	)
Effect of foreign exchange rates		40,839
Balance at December 31, 2020		9,808
New deferrals, net of amounts recognized in the current period		—
Amounts returned to customers		(9,808	)
Effect of foreign exchange rates		—
Balance at December 31, 2021	$	—

Contract assets

The Company had approximately $0 and $18,000 of contract assets as of December 31, 2021 and 2020 respectively, which are generated when contractual billing schedules differ from revenue recognition timing. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

Unsatisfied performance obligations

The Company had no unsatisfied performance obligations related to its contracts with customers at December 31, 2021 and 2020.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Fair value measurements

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair value measurements

Note 6 - Fair value measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

•

Level 1 - defined as observable inputs such as quoted prices in active markets;

•

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

•

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

For the year ended December 31, 2021, the Company has not transferred any assets between fair value measurement levels.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.

In June 2019, Curetis drew down a third tranche of EUR 5.0 million from the European Investment Bank (“EIB”). In return for EIB waiving the condition precedent of a minimum cumulative equity capital raised of EUR 15 million to disburse this EUR 5.0 million tranche, the parties agreed on a 2.1% participation percentage interest (“PPI”). Upon maturity of the tranche, EIB would be entitled to an additional payment that is equity-linked and equivalent to 2.1% of the then total valuation of Curetis N.V. On July 9, 2020, the Company negotiated an amendment to the EIB debt financing facility. As part of the amendment, the parties adjusted the PPI percentage applicable to the previous EIB tranche of EUR 5.0 million which was funded in June 2019 from its original 2.1% PPI in Curetis N.V.’s equity value upon maturity to a new 0.3% PPI in OpGen's equity value upon maturity between mid-2024 and mid-2025. This right constitutes an embedded derivative, which is separated and measured at fair value with changes being accounted for through profit or loss. The Company determines the fair value of the derivative using a Monte Carlo simulation model. Using this model, level 3 unobservable inputs include estimated discount rates and estimated risk-free interest rates.

F-21

The Company’s convertible debt with YA II PN, LTD (see Note 7) included a conversion feature which constitutes an embedded derivative, which was separated and measured at fair value with subsequent changes being accounted for through profit or loss. The Company determines the fair value of the derivative using a Monte Carlo simulation model. Using this model, level 3 unobservable inputs include estimated volatility rates and estimated risk-free interest rates.

The fair value of level 3 liabilities measured at fair value on a recurring basis for the years ended December 31, 2021 and 2020 was as follows:

Description

Balance at

December 31,

2020

Change in Fair

Value

Effect of Foreign

Exchange Rates

Balance at

December 31,

2021

Participation percentage interest liability

112,852

129,731

(13,994

)

228,589

Total revenue

112,852

129,731

(13,994

)

228,589

Description	Balance at December 31, 2019		Acquired from Curetis		Change in Fair Value			Effect of Foreign Exchange Rates		Balance at December 31, 2020
Participation percentage interest liability	$	—	$	173,373	$	(75,222	)	$	14,701	$	112,852
Embedded conversion option liability		—		442,458		(442,458	)		—		—
Total revenue	$	—	$	615,831	$	(517,680	)	$	14,701	$	112,852

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when a triggering event requires such evaluation. During the year ended December 31, 2020, the Company recorded impairment expense of $750,596 related to its intangible assets and $101,838 related to its ROU assets (see Note 3). During the year ended December 31, 2021, the Company recorded impairment expense of $170,714 related to its ROU assets (see Note 3).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Debt

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Debt

Note 7 - Debt

The following table summarizes the Company’s long-term debt and short-term borrowings as December 31, 2021 and 2020:

	December 31,
	2021			2020
EIB	$	25,161,855		$	25,936,928
PPP		—			259,353
MGHIF		—			331,904
Insurance financings		—			107,742
Total debt obligations		25,161,855			26,635,927
Unamortized debt discount		(3,466,491	)		(6,557,992	)
Carrying value of debt		21,695,364			20,077,935
Less current portion		(14,519,113	)		(699,000	)
Long-term debt	$	7,176,251		$	19,378,935

MGHIF financing

In July 2015, the Company entered into a Purchase Agreement with MGHIF, pursuant to which MGHIF purchased 2,273 shares of common stock of the Company at $2,200 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to MGHIF an 8% Senior Secured Promissory Note (the “MGHIF Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company’s obligations under the MGHIF Note were secured by a lien on all of OpGen’s assets excluding the assets of Curetis GmbH, Curetis USA, and Ares Genetics.

On June 28, 2017, the MGHIF Note was amended and restated, and the maturity date of the MGHIF Note was extended by one year to July 14, 2018. As consideration for the agreement to extend the maturity date, the Company issued an amended and restated secured promissory note to MGHIF that (1) increased the interest rate to ten percent (10%) per annum and (2) provided for the issuance of common stock warrants to purchase 656 shares of its common stock to MGHIF.

On June 11, 2018, the Company executed an Allonge to the MGHIF Note. The Allonge provided that accrued and unpaid interest of $285,512 due as of July 14, 2018, the original maturity date, be paid through the issuance of shares of OpGen's common stock in a private placement transaction. In addition, the Allonge revised and extended the maturity date for payment of the MGHIF Note to six semi-annual payments of $166,667 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021. The Allonge to the MGHIF Note was treated as a debt modification and, as such, the unamortized issuance costs of approximately $7,000 as of June 11, 2018 were deferred and amortized as incremental expense over the term of the MGHIF Note. During the year ended December 31, 2021, the Company made the final payment under the MGHIF Note and the lien on the Company’s assets was released.

Yorkville Convertible Notes

The Company agreed to assume, as a condition to closing the business combination with Curetis all of the outstanding convertible notes (the “Convertible Notes”) issued by Curetis N.V. in favor of YA II PN, LTD (“Yorkville”), pursuant to that certain Agreement for the Issuance of and Subscription to Notes Convertible into Shares and Share Subscription Warrants, dated October 2, 2018, by and between Curetis N.V. and Yorkville.

On February 24, 2020, the Company entered into an Assignment of the Agreement for the Issuance of and Subscription to Notes Convertible into Shares (the “Assignment Agreement”) with Curetis N.V. and Yorkville. Pursuant to the Assignment Agreement, upon assumption of the Convertible Notes by the Company, the Convertible Notes ceased to be convertible into shares of Curetis N.V. and are instead convertible into shares of the Company’s common stock, par value $0.01. The Assignment Agreement provided that an amount of 500,000 shares of the Company’s common stock that comprise a portion of the consideration payable by the Company under the Implementation Agreement be reserved for issuance under the Convertible Notes. On June 17, 2020, the Company registered for resale an additional 450,000 shares of Company common stock issuable upon conversion of the Convertible Notes.

F-23

At closing of the Transaction, an aggregate amount of €1.3 million of unconverted Convertible Notes was assumed by the Company. The Convertible Notes were measured and recognized at fair value at the acquisition date. The fair value of the Convertible Notes as of the closing of the Transaction was approximately $1.3 million. The resulting debt discount was amortized over the life of the Convertible Notes as an increase in interest expense. During year ended December 31, 2020, the Company issued 763,905 shares of common stock in satisfaction of approximately $1,451,000 of Convertible Notes. As of December 31, 2020, all notes have been converted.

EIB Loan Facility

In 2016, Curetis entered into a contract for an up to €25 million senior, unsecured loan financing facility from the European Investment Bank (“EIB”). The financing is in the first growth capital loan under the European Growth Finance Facility (“EGFF”), launched in November 2016. It is backed by a guarantee from the European Fund for Strategic Investment (“EFSI”), EFSI is an essential pillar of the Investment Plan for Europe (“IPE”), under which the EIB and the European Commission are working as strategic partners to support investments and bring back jobs and growth to Europe.

The funding can be drawn in up to five tranches within 36 months, under the EIB amendment, and each tranche is to be repaid upon maturity five years after draw-down.

In April 2017, Curetis drew down a first tranche of €10 million from this facility. This tranche has a floating interest rate of EURIBOR plus 4% payable after each 12-month-period from the draw-down-date and another additional 6% interest per annum that is deferred and payable at maturity together with the principal. In June 2018, another tranche of €3 million was drawn down. The terms and conditions are analogous to the first one.

In June 2019, Curetis drew down a third tranche of €5 million from the EIB. In line with all prior tranches, the majority of interest is also deferred into the bullet repayment structure upon maturity. In return for EIB waiving the condition precedent of a minimum cumulative equity capital raised of €15 million to disburse this €5 million tranche, the parties agreed on a 2.1% PPI. Upon maturity of the tranche, not before approximately mid-2024 (and no later than mid-2025) EIB would be entitled to an additional payment that is equity-linked and equivalent to 2.1% of the then total valuation of Curetis N.V. As part of the amendment between the Company and EIB on July 9, 2020, the parties adjusted the PPI percentage applicable to the previous EIB tranche of €5 million which was funded in June 2019 from its original 2.1% PPI in Curetis N.V.’s equity value upon maturity to a new 0.3% PPI in OpGen’s equity value upon maturity. This right constitutes an embedded derivative, which is separated and measured at fair value with changes being accounted for through income or loss.

On July 10, 2020, EIB agreed to defer total interest payments of €720k due in April and June 2020 under the first three tranches of the debt financing facility until December 31, 2021. The Company made these interest payments in December 2020.

The EIB debt was measured and recognized at fair value as of the acquisition date. The fair value of the EIB debt was approximately $15.8 million as of the acquisition date. The resulting debt discount will be amortized over the life of the EIB debt as an increase to interest expense.

As of December 31, 2021, the outstanding borrowings under all tranches were €22,216,012 (approximately USD $25,161,855), including deferred interest payable at maturity of €4,216,012 (approximately USD $4,775,055).

PPP

On April 22, 2020, the Company entered into a Term Note (the “Company Note”) with Silicon Valley Bank (the “Bank”) pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration. The Company’s wholly-owned subsidiary, Curetis USA Inc. (“Curetis USA” and collectively with the Company, the “Borrowers”), also entered into a Term Note with the Bank (the “Subsidiary Note,” and collectively with the Company Note, the “Notes”). The Notes were dated April 22, 2020. The principal amount of the Company Note was $879,630, and the principal amount of the Subsidiary Note was $259,353.

F-24

In accordance with the requirements of the CARES Act, the Borrowers will use the proceeds from the Notes in accordance with the requirements of the PPP to cover certain qualified expenses, including payroll costs, rent and utility costs. Interest accrues on the Notes at the rate of 1.00% per annum. The Borrowers may apply for forgiveness of amounts due under the Notes, in an amount equal to the sum of qualified expenses under the PPP, which include payroll costs, rent obligations, and covered utility payments incurred during the twenty-four weeks following disbursement under the Notes. The entire proceeds were used under the Notes for such qualifying expenses. The Company Note was forgiven in November 2020. In May 2021, the Subsidiary Note was forgiven.

Total interest expense (including accretion of fair value to face value and amortization of debt discounts and financing fees) on all debt instruments was $4,799,331 and $3,399,984 for the years ended December 31, 2021 and 2020, respectively.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2021

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Note 8 - Stockholders’ Equity

As of December 31, 2021, the Company has 100,000,000 shares of authorized common shares and 46,450,250 shares issued and outstanding, and 10,000,000 of authorized preferred shares, of which none were issued or outstanding.

Following receipt of approval from stockholders at a special meeting of stockholders held on December 8, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to increase the authorized shares of common stock from 50,000,000 to 100,000,000 shares.

Following receipt of approval from stockholders at a special meeting of stockholders held on January 17, 2018, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, at a ratio of one share for twenty-five shares. Additionally, following receipt of approval from stockholders at a special meeting of stockholders held on August 22, 2019, the Company filed an additional amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, at a ratio of one share for twenty shares. All share amounts and per share prices in this Annual Report have been adjusted to reflect the reverse stock splits.

On October 28, 2019, the Company closed the October 2019 Public Offering of 2,590,170 units at $2.00 per unit and 2,109,830 pre-funded units at $1.99 per pre-funded unit. The offering raised gross proceeds of approximately $9.4 million and net proceeds of approximately $8.3 million. During the year ended December 31, 2021, 5,000 common warrants were exercised raising net proceeds of $10,000. During the year ended December 31, 2020, 4,341,000 common warrants were exercised raising net proceeds of approximately $8.7 million.

On February 11, 2020, the Company entered into an ATM Agreement with Wainwright, which we amended and restated on November 13, 2020 to add BTIG, LLC pursuant to which the Company may offer and sell from time to time in an “at the market offering,” at its option, up to an aggregate of $22.1 million of shares of the Company's common stock through the sales agents. During the year ended December 31, 2020, the Company sold 7,521,610 shares of its common stock under the 2020 ATM Offering resulting in aggregate net proceeds to the Company of approximately $15.8 million, and gross proceeds of $16.7 million. During the year ended December 31, 2021, the Company sold 680,000 shares of its common stock under the 2020 ATM Offering resulting in aggregate net proceeds to the Company of approximately $1.48 million, and gross proceeds of $1.55 million. As of December 31, 2021, remaining availability under the ATM Agreement is $3.9 million.

On April 1, 2020, the Company acquired all of the shares of Curetis GmbH, and certain other assets and liabilities of Curetis N.V., as further described in Notes 1 and 4, and paid, as the sole consideration, 2,028,208 shares of the Company’s common stock to the Seller.

On November 25, 2020, the Company closed a private placement with one healthcare-focused U.S. institutional investor of (i) 2,245,400 shares of common stock together with 2,245,400 common warrants to purchase up to 2,245,400 shares of common stock and (ii) 2,597,215 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with 2,597,215 common warrants to purchase up to 2,597,215 shares of common stock (the “2020 PIPE”). Each share of common stock and accompanying common warrant were sold together at a combined offering price of $2.065, and each pre-funded warrant and accompanying common warrant were sold together at a combined offering price of $2.055. The common warrants have an exercise price of $1.94 per share, and are exercisable commencing on the six month anniversary of the date of issuance, and will expire five and one half (5.5) years from the date of issuance. The 2020 PIPE raised aggregate net proceeds of $9.3 million, and gross proceeds of $10.0 million. As of December 31, 2020, all 2,597,215 pre-funded warrants issued in the 2020 PIPE have been exercised.

F-25

On February 11, 2021, the Company closed the February 2021 Offering with a single U.S.-based, healthcare-focused institutional investor for the purchase of (i) 2,784,184 shares of common stock and (ii) 5,549,149 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock. The Company also issued to the investor, in a concurrent private placement, unregistered common warrants to purchase 4,166,666 shares of the Company’s common stock. Each share of common stock and accompanying common warrant were sold together at a combined offering price of $3.00, and each pre-funded warrant and accompanying common warrant were sold together at a combined offering price of $2.99. The pre-funded warrants are immediately exercisable, at an exercise price of $0.01, and may be exercised at any time until all of the pre-funded warrants are exercised in full. The common warrants will have an exercise price of $3.55 per share, will be exercisable commencing on the six-month anniversary of the date of issuance, and will expire five and one-half (5.5) years from the date of issuance. The February 2021 Offering raised aggregate net proceeds of $23.5 million, and gross proceeds of $25.0 million. As of December 31, 2021, all pre-funded warrants issued in the February 2021 Offering have been exercised.

On March 9, 2021, the Company entered into an Exercise Agreement with the Holder from our 2020 PIPE financing. Pursuant to the Exercise Agreement, in order to induce the Holder to exercise all of the remaining 4,842,615 Existing Warrants for cash, pursuant to the terms of and subject to beneficial ownership limitations contained in the Existing Warrants, the Company agreed to issue to the Holder, New Warrants to purchase 0.65 shares of common stock for each share of common stock issued upon such exercise of the remaining Existing Warrants pursuant to the Exercise Agreement for an aggregate of 3,147,700 New Warrants. The terms of the New Warrants are substantially similar to those of the Existing Warrants, except that the New Warrants have an exercise price of $3.56. The New Warrants are immediately exercisable and will expire five years from the date of the Exercise Agreement. The Holder paid an aggregate of $255,751 to the Company for the purchase of the New Warrants. The Company received aggregate gross proceeds before expenses of approximately $9.65 million from the exercise of the remaining Existing Warrants held by the Holder and the payment of the purchase price for the New Warrants. The Company recognized approximately $7.8 million of non-cash warrant inducement expense during year ended December 31, 2021 related to this transaction representing the fair value of the New Warrants issued to induce the exercise. The fair values were calculated using the Black-Scholes option pricing model.

On October 18, 2021, the Company closed the October 2021 Offering with a single healthcare-focused institutional investor of 150,000 shares of convertible preferred stock and warrants to purchase up to an aggregate of 7,500,000 shares of common stock. The shares of preferred stock had a stated value of $100 per share and were converted into an aggregate of 7,500,000 shares of common stock at a conversion price of $2.00 per share after the Company received stockholder approval for an increase to its number of authorized shares of common stock, which approval occurred at the Company’s special meeting of stockholders held in December 2021. The warrants have an exercise price of $2.05 per share, will become exercisable six months following the date of issuance, and will expire five years following the initial exercise date. The warrants are classified as permanent equity at December 31, 2021. In connection with the issuance of convertible preferred stock, the Company recognized a beneficial conversion feature of $7,166,752 as a deemed dividend to the preferred stockholders.

On December 8, 2021, the Company received shareholder approval to increase the number of authorized shares of common stock of the Company. As of December 31, 2021, all 150,000 shares of convertible preferred stock were converted into an aggregate of 7,500,000 shares of common stock. The October 2021 Offering raised aggregate net proceeds of $13.9 million, and gross proceeds of $15.0 million.

Stock options

In 2008, the Board adopted, and the stockholders approved, the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), pursuant to which the Company’s Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Board adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan (the “2015 Plan”); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s IPO. Following the effectiveness of the 2015 Plan, no further grants have been made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

F-26

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 2,710 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of December 31, 2021, 465,586 shares remain available for issuance under the 2015 Plan.

On September 30, 2020, the Company held its 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). At the 2020 Annual Meeting, stockholders of the Company voted to approve, among other things, a plan under which stock options to purchase an aggregate of 1,300,000 shares of the Company’s common stock would be made by the Board of Directors of the Company outside of the stockholder-approved equity incentive plan to its executive officers and non-employee directors (the “2020 Stock Options Plan”). The 2020 Stock Options Plan and the grant made thereunder were approved by the Board of Directors on August 6, 2020, subject to receipt of stockholder approval at the 2020 Annual Meeting. The aggregate number of shares of the Company’s common stock authorized for issuance is 1,300,000 shares of common stock and all 1,300,000 stock options were issued on September 30, 2020. Shares subject to awards granted under the 2020 Stock Options Plan that are forfeited or terminated before being exercised will not be available for re-issuance under the 2020 Stock Options Plan. As of December 31, 2021, no shares remain available for issuance under the 2020 Stock Options Plan.

Replacement awards

In connection with the business combination with Curetis, the Company issued equity awards to Curetis employees (“2016 Plan”), consisting of stock options (“replacement awards”) in exchange for their Curetis equity awards. The replacement awards consisted of 134,371 stock options with a weighted average grant date fair value of $1.68. The terms of these replacement awards are substantially similar to the original Curetis equity awards. The fair value of the replacement awards for services rendered through April 1, 2020, the acquisition date, was recognized as a component of the purchase consideration, with the remaining fair value of the replacement awards related to the post-combination services recorded as stock-based compensation over the remaining vesting period.

For the years ended December 31, 2021 and 2020, the Company recognized stock compensation expense as follows:

	Years Ended December 31,
	2021		2020
Cost of services	$	10,299	$	2,927
Research and development		232,319		62,783
General and administrative		553,557		231,010
Sales and marketing		82,400		19,366
	$	878,575	$	316,086

No income tax benefit for stock-based compensation arrangements was recognized in the consolidated statements of operations due to the Company’s net loss position.

As of December 31, 2021, the Company had unrecognized expense related to its stock options of $1.0 million, which will be recognized over a weighted average period of 2.5 years.

F-27

A summary of the status of options granted is presented below as of and for the years ended December 31, 2021 and 2020:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding at December 31, 2019		9,654		$	418.10		8.0	$	—
Granted		1,525,000		$	2.13
Exercised		—		$	—
Assumed in business combination		134,371		$	48.40
Forfeited		(3,631	)	$	21.11
Expired		(872	)	$	473.92
Outstanding at December 31, 2020		1,664,522		$	7.99		9.4	$	—
Granted		415,000		$	1.99
Exercised		—		$	—
Forfeited		(363,554	)	$	2.17
Expired		(2,619	)	$	544.38
Outstanding at December 31, 2021		1,713,349		$	6.88		8.5	$	—
Vested and expected to vest		1,713,349		$	6.88		8.5	$	—
Exercisable at December 31, 2021		731,090		$	10.45		8.0	$	—

The total fair value of options vested in the years ended December 31, 2021 and 2020 was $622,757 and $549,341, respectively. The fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model based on the assumptions below:

	Years Ended December 31,
	2021		2020
Annual dividend		—		—
Expected life (in years)		5.75 - 6.00		5.25 - 6.25
Risk free interest rate		0.9% - 1.1%		0.3% - 0.5%
Expected volatility		121.3% - 123.1%		40.9% - 46.6%

Restricted stock units

A summary of the status of restricted stock units granted is presented below as of and for the years ended December 31, 2021 and 2020:

	Number of Units			Weighted-Average Grant Date Fair Value
Unvested at December 31, 2019		14,975		$	8.76
Granted		—		$	—
Vested		(5,924	)	$	8.51
Forfeited		(933	)	$	8.84
Unvested at December 31, 2020		8,118		$	8.93
Granted		360,000		$	1.99
Vested		(3,768	)	$	8.94
Forfeited		(78,085	)	$	2.23
Unvested at December 31, 2021		286,265		$	2.03

As of December 31, 2021, there was approximately $320,000 of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of 1 years.

F-28

Stock purchase warrants

At December 31, 2021 and 2020, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at December 31,
Issuance		Exercise Price	Expiration	2021 (1)	2020 (1)
November 2011	$	3,955.00	November 2021	—	15
December 2011	$	3,955.00	December 2021	—	2
February 2015	$	3,300.00	February 2025	451	451
May 2016	$	656.20	May 2021	—	9,483
June 2016	$	656.20	May 2021	—	4,102
June 2017	$	390.00	June 2022	938	938
July 2017	$	345.00	July 2022	318	318
July 2017	$	250.00	July 2022	2,501	2,501
July 2017	$	212.60	July 2022	50,006	50,006
February 2018	$	81.25	February 2023	9,232	9,232
February 2018	$	65.00	February 2023	92,338	92,338
October 2019	$	2.00	October 2024	354,000	359,000
October 2019	$	2.60	October 2024	235,000	235,000
November 2020	$	1.94	May 2026	—	4,842,615
November 2020	$	2.68	May 2026	242,130	242,130
February 2021	$	3.55	August 2026	4,166,666	—
February 2021	$	3.90	August 2026	416,666	—
March 2021	$	3.56	March 2026	3,147,700	—
October 2021	$	2.05	April 2027	7,500,000	—
				16,217,946	5,848,131

The warrants listed above were issued in connection with various equity, debt, preferred stock or development contract agreements.


(1)	Warrants to purchase fractional shares of common stock resulting from the reverse stock split on August 22, 2019 were rounded up to the next whole share of common stock on a holder by holder basis.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Note 9 - Income Taxes

The Company’s loss before income taxes was $34.8 million and $26.1 million for the years ended December 31, 2021 and 2020, respectively.

The Company’s provision for income taxes consists of the following for the years ended December 31, 2021 and 2020:

	December 31,
	2021		2020
Current income tax provision
Federal	$	36,084	$	—
State		7,744		—
Foreign		—		132,403
Total		43,828		132,403
Deferred income tax provision
Federal		—		—
State		—		—
Foreign		—		—
Total		—		—
Total provision for income taxes	$	43,828	$	132,403

F-29

At December 31, 2021 and 2020, the Company had deferred tax assets of $106,839,267 and $103,185,302, respectively, primarily consisting of NOL carryforwards, research and development (“R&D”) credits, and differences between depreciation and amortization recorded for financial statement and tax purposes. The Company’s net deferred tax assets at December 31, 2021 and 2020 have been offset by a valuation allowance of $106,088,316 and $98,874,420, respectively. The valuation allowance has been recorded due to the uncertainty of realization of the deferred tax assets. The Company’s deferred tax assets and liabilities as of December 31, 2021 and 2020 are as follows:

	December 31,
	2021			2020
Deferred tax assets:
NOL carryforward	$	102,388,393		$	98,165,790
R&D credit carryforward		2,559,479			2,559,479
Share-based compensation		498,658			319,397
Depreciation		—			100,157
Interest expense		502,575			1,233,203
ROU liabilities		567,624			475,645
Accruals and other		322,538			331,631
Total deferred tax assets		106,839,267			103,185,302
Valuation allowance		(106,088,316	)		(98,874,420	)
Deferred tax liabilities:
Intangible assets		(178,478	)		(3,885,485	)
ROU assets		(225,057	)		(425,397	)
Depreciation		(347,416	)		—
Net	$	—		$	—

The difference between the Company’s expected income tax provision (benefit) from applying federal statutory tax rates to the pre-tax loss and actual income tax provision (benefit) relates to the effect of the following:

	2021			2020
Federal income tax benefit at statutory rates		21.0	%		21.0	%
Permanent adjustment		(4.4	)%		0.6	%
Provision to return adjustment		(0.1	)%		—
State income tax benefit, net of federal benefit		1.6	%		3.5	%
Foreign rate differential		2.4	%		2.8	%
Change in valuation allowance		(20.6	)%		(28.4	)%
		(0.1	)%		(0.5	)%

Management followed the guidance in ASC 740, which states that “a cumulative loss in recent years is a significant piece of negative evidence that is difficult to overcome” and concluded that the Company’s net deferred tax assets were not realizable as of December 31, 2021 and 2020. Accordingly, a valuation allowance of $106.1 million and $98.9 million has been recorded to offset the net deferred tax assets.

The Company has federal NOL carryforwards of $202,015,062 and $196,511,928 at December 31, 2021 and 2020, respectively. The Company also has total Foreign NOL carryforwards at December 31, 2021 of $170,607,782 which is primarily driven by the Company's operations in Germany. The NOL carryforwards incurred prior to 2018 begin to expire in 2022. In December 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "Tax Act"), most of the provisions of which took effect starting in 2018. Under the Tax Act, the amount of post 2017 NOLs that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. In addition, the Tax Act generally eliminates the ability to carry back any NOL to prior taxable years, while allowing post 2017 unused NOLs to be carried forward indefinitely. Utilization of the NOL carryforward may be subject to an annual limitation as provided by Section 382 of the Code, defined earlier. There can be no assurance that the NOL carryforward will ever be fully utilized. To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code, as amended. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

F-30

On March 27, 2020, the United States enacted the CARES Act. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions which are expected to impact the Company's financial statements include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company doesn't believe that the CARES Act will have a material impact on its financial position, results of operations, or cash flows.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 10 - Commitments and Contingencies

Registration and other stockholder rights

In connection with the various investment transactions, the Company entered into registration rights agreements with stockholders, pursuant to which the investors were granted certain demand registration rights and/or piggyback and/or resale registration rights in connection with subsequent registered offerings of the Company’s common stock.

Supply agreements

In June 2017, the Company entered into an agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific (“LTC”), to supply the Company with Thermo Fisher Scientific’s QuantStudio 5 Real-Time PCR Systems (“QuantStudio 5”) to be used to run OpGen’s Acuitas AMR Gene Panel tests. Under the terms of the agreement, the Company must notify LTC of the number of QuantStudio 5s that it commits to purchase in the following quarter. As of December 31, 2021, the Company had acquired twenty-four QuantStudio 5s including none during the year ended December 31, 2021. As of December 31, 2021, the Company has not committed to acquiring additional QuantStudio 5s in the next three months.

Curetis places frame-work orders for Unyvero-Systems and for raw materials for its cartridge manufacturing to ensure availability during commercial ramp-up-phase and also to gain volume-scale-effects with regards to purchase prices. Some of the electronic parts used for the production of Unyvero-Systems have lead times of many months, hence it is necessary to order such systems with long-term framework-orders to ensure the demands from the market are covered. The aggregate purchase commitments over the next twelve months are approximately $0.9 million.

COVID-19 Impact

In December 2019 and early 2020, the coronavirus known as COVID-19 was reported to have surfaced in China. The spread of this virus including its variants and mutations globally in 2020 and 2021 as well as into 2022 has caused significant business disruption domestically in the United States and in Europe, as well as China, the areas in which the Company primarily operates or has significant business interest. While the disruption is currently expected to be temporary, such disruption is still ongoing and there remains considerable uncertainty around the duration of this disruption. Therefore, while the Company expects that this matter will continue to impact the Company’s financial condition, results of operations, or cash flows, the extent of the financial impact and duration cannot be reasonably estimated at this time.

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Leases

Note 11 - Leases

The following table presents the Company’s ROU assets and lease liabilities as of December 31, 2021 and 2020:

Lease Classification	December 31, 2021		December 31, 2020
ROU Assets:
Operating	$	1,814,396	$	2,082,300
Financing		90,467		449,628
Total ROU assets	$	1,904,863	$	2,531,928
Liabilities
Current:
Operating	$	459,792	$	964,434
Finance		43,150		266,470
Noncurrent:
Operating		2,977,402		1,492,544
Finance		3,644		46,794
Total lease liabilities	$	3,483,988	$	2,770,242

Maturities of lease liabilities as of December 31, 2021 by year are as follows:

Maturity of Lease Liabilities	Operating			Finance			Total
2022	$	745,850		$	44,850		$	790,700
2023		639,172			3,364			642,536
2024		648,767			280			649,047
2025		544,080			—			544,080
2026		378,279			—			378,279
Thereafter		2,126,371			—			2,126,371
Total lease payments		5,082,519			48,494			5,131,013
Less: Interest		(1,645,325	)		(1,700	)		(1,647,025	)
Present value of lease liabilities	$	3,437,194		$	46,794		$	3,483,988

Consolidated statements of operations classification of lease costs as of the years ended December 31, 2021 and 2020 are as follows:

		Years ended December 31,
Lease Cost	Classification	2021		2020
Operating	Operating expenses	$	1,055,595	$	1,205,551
Finance:
Amortization	Operating expenses		359,162		508,962
Interest expense	Other expenses		15,481		57,247
Total lease costs		$	1,430,238	$	1,771,760

Other lease information as of December 31, 2021 is as follows:

Other Information	Total
Weighted average remaining lease term (in years)
Operating leases		7.6
Finance leases		0.9
Weighted average discount rate:
Operating leases		8.9	%
Finance leases		9.1	%

F-32

Supplemental cash flow information for the years ended December 31, 2021, and 2020 is as follows:

Supplemental Cash Flow Information	2021		2020
Cash paid for amounts included in the measurement of lease liabilities
Cash used in operating activities
Operating leases	$	1,055,595	$	1,205,551
Finance leases	$	15,481	$	57,247
Cash used in financing activities
Finance leases	$	266,470	$	579,029
ROU assets obtained in exchange for lease obligations:
Operating leases	$	615,761	$	1,008,039
Finance leases	$	—	$	—

License Agreements, Research Collaborations and Development Agreements

12 Months Ended

Dec. 31, 2021

License Agreements Research Collaborations And Development Agreements [Abstract]

License Agreements, Research Collaborations and Development Agreements

Note 12 - License Agreements, Research Collaborations and Development Agreements

NYSDOH

In 2018, the Company announced a collaboration with the New York State Department of Health (“DOH”) and ILÚM Health Solutions, LLC (“ILÚM”), a wholly-owned subsidiary of Merck’s Healthcare Services and Solutions division, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide. ILÚM has since been acquired by Infectious Disease Connect, Inc. (“IDC”), a University of Pittsburgh Medical Center (“UPMC”) Enterprise company. The Company is working together with DOH’s Wadsworth Center and IDC to continue development of an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance. As part of the collaboration, the Company received approximately $1.6 million over the 15-month demonstration portion of the project. The demonstration project began in early 2019 and was completed in the first quarter of 2020. In April 2020, the Company began a second-year expansion phase to build on the successes and experience of the first-year pilot phase while focusing on accomplishing the goal of the effort to improve patient outcomes and save healthcare dollars by integrating real-time epidemiologic surveillance with rapid delivery of antibiotic resistance results to care-givers via web-based and mobile platforms. The second-year contract included a quarterly retainer-based project fee as well as volume-dependent per test fees for a total contract value of up to $450,000 to OpGen. In April 2021, the Company extended its second-year expansion phase by another six months through September 30, 2021 at which point the project was completed and has ended. The six-month extension and expansion contract included a quarterly retainer-based project fee as well as volume-dependent per test fees for a total contract value of up to an additional $540,000. During the years ended December 31, 2021 and 2020, the Company recognized $558,000 and $388,000 of revenue related to the contract, respectively.

Sandoz

In December 2018, Ares Genetics entered into a service frame agreement with Sandoz International GmbH (“Sandoz”), to leverage Ares Genetics’ database on the genetics of antibiotic resistance, ARESdb, and the ARES Technology Platform for Sandoz’ anti-infective portfolio.

Under the terms of the frame agreement, which had an initial term of 36 months and recently been extended to end January 31, 2025, Ares Genetics and Sandoz intend to develop a digital anti-infectives platform, combining established microbiology laboratory methods with advanced bioinformatics and artificial intelligence methods to support drug development and life-cycle management. The collaboration, in the short- to mid-term, aims to both rapidly and cost-effectively re-purpose existing antibiotics and design value-added medicines with the objective of expanding indication areas and to overcome antibiotic resistance, in particular with regards to infections with bacteria that has already developed resistance against multiple treatment options. In the longer-term, the platform is expected to enable surveillance for antimicrobial resistant pathogens to inform antimicrobial stewardship and the development of novel anti-infectives that are less prone to encounter resistance and thereby preserve antibiotics as an effective treatment option.

F-33

The agreement covers the first phases of the collaboration with Sandoz and provides certain moderate six-figure R&D funding to Ares Genetics. No milestones or royalties were agreed to as part of this first phase of the collaboration. The agreement may be terminated by Sandoz effective immediately at any time with written notice.

Qiagen

On February 18, 2019, Ares Genetics and Qiagen GmbH, or Qiagen, entered into a strategic licensing agreement for ARESdb and AREStools, in the area of antimicrobial resistance (“AMR”) research. The agreement has a term of 20 years and may be terminated by Qiagen for convenience with 180 days written notice.

Ares Genetics has retained the rights to use ARESdb and AREStools for AMR research, customized bioinformatics services, and for the development of specific AMR assays and applications for the Curetis Group (including Ares Genetics), as well as third parties (e.g., other diagnostics companies or partners in the pharmaceutical industry). As the Qiagen research offering is expected to also enable advanced molecular diagnostic services and products, Qiagen’s customers may obtain a diagnostic use license from Ares Genetics.

Under the terms of the original agreement, Qiagen, in exchange for a moderate six figure up-front licensing payment, has received an exclusive RUO license to develop and commercialize general bioinformatics offerings and services for AMR research use only, based on Ares Genetics’ database on the genetics of antimicrobial resistance, ARESdb, as well as on the ARES bioinformatics AMR toolbox, AREStools. Under the agreement, the parties had agreed to a mid-single digit percentage royalty rate on Qiagen net sales, which is subject to a minimum royalty rate that steps up upon certain achieved milestones, which is payable to Ares Genetics. The parties also agreed to further modest six figure milestone payments upon certain product launches. The contract was subsequently amended in May 2021 to a non-exclusive license and a flat annual license fee as well as a royalty percentage on potential future panel based products that are developed by Qiagen.

Global leading IVD corporation

On September 16, 2019, Ares Genetics entered into a multi-phase partnership with an undisclosed leading global in vitro diagnostics corporation, or the Partner, to jointly develop diagnostic solutions for infectious disease testing, based on next-generation sequencing, or NGS, technology. Ares Genetics and the Partner also entered into an R&D option agreement for the first phase of the partnership. Ares Genetics received an option fee of approximately $550,000. The initial 10-month term of the R&D collaboration, ended July 13, 2020, with payments excluding the option fee of approximately $1.2 million.

In the first phase of the collaboration, which lasted 10 months, the parties have further enriched ARESdb with a focus on certain pathogens relevant in a first, undisclosed infectious disease indication. Additional clinical isolates of such pathogens have been sequenced by Ares Genetics at its recently established NGS laboratory in Vienna, Austria. Based on this enlarged and enriched dataset, Ares Genetics has further developed the algorithms for predictive antibiotic resistance testing for drug/pathogen combinations particularly relevant in the targeted indication to enable NGS-based infectious disease diagnostics.

Under the initial agreement, the Partner funded Ares Genetics’ R&D activities for the genotypic and phenotypic characterization of additional bacterial strains to augment ARESdb and the development of optimized algorithms for predicting antibiotic resistance. Furthermore, in return for the up-front option fee, the Partner obtained a three-month right for first negotiation for an exclusive human clinical diagnostic use license to ARESdb and the ARES Technology Platform. A license was not executed and the collaboration ended in early 2021.

The Company recognized approximately $0 and $870,000 of revenue related to the contract during the years ended December 31, 2021 and 2020, respectively.

F-34

FISH License

The Company was party to one license agreement with Life Technologies to acquire certain patent rights and technologies related to its FISH product line. Royalties were incurred upon the sale of a product or service which utilizes the licensed technology. The Company terminated this license agreement in October 2020 effective as of June 30, 2021 in conjunction with its announced exit of the FISH business in June 2021. The Company paid a one-time settlement fee of $350,000 and paid a 10% royalty on the sale of eligible products through June 2021 but is no longer subject to any minimum royalty obligations. The Company recognized net royalty expense related to this license of $11,721 and $(68,854) for the years ended December 31, 2021 and 2020, respectively.

Siemens

In 2016, Ares Genetics acquired the GEAR assets from Siemens Technology Accelerator GmbH (STA), providing the original foundation to ARESdb. Under the agreement with STA, Ares Genetics incurs royalties on revenues from licensed product sales or sublicensing proceeds. Royalty rates under the Siemens agreement range from 1.3% to 40% depending on the specifics of the licenses and rights provided by Ares Genetics to third parties and whether such third parties may have been originally introduced by Siemens to Ares Genetics. The total net royalty expense related to this agreement was $146,375 and $2,775 for the years ended December 31, 2021 and 2020, respectively.

Related Party Transactions

12 Months Ended

Dec. 31, 2021

Related Party Transactions

Note 13 - Related Party Transactions

On April 1, 2020, as part of the Transaction, Oliver Schacht, Ph.D., the former CEO of Curetis N.V., was appointed as the CEO of the Company, and Johannes Bacher the former COO of Curetis N.V. was appointed as the COO of the Company. Effective April 1, 2020, Mr. Schacht and Mr. Bacher were appointed as liquidators of Curetis N.V. in liquidation and Curetis GmbH was designated as Custodian of the Books for Curetis N.V. During a portion of the year ended December 31, 2020, Curetis N.V. in liquidation processed payroll for Mr. Schacht and Mr. Bacher and invoiced OpGen and Curetis GmbH, respectively, in line with their signed management agreements.

Subsequent Events

12 Months Ended

Dec. 31, 2021

Subsequent Events [Abstract]

Subsequent Events

Note 14 - Subsequent Events

The Company’s management reviewed all material events through the date the consolidated financial statements were issued for subsequent event disclosure consideration, and none were noted.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

Foreign Currency

Use of Estimates

Fair value of financial instruments

For additional fair value disclosures, see Note 6.

Cash, cash equivalents and restricted cash

Cash and cash equivalents and restricted cash

F-11

	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	36,080,392	$	13,360,463
Restricted cash		551,794		746,792
Total cash and cash equivalents and restricted cash in the consolidated statements of cash flows	$	36,632,186	$	14,107,255

Accounts receivable

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	December 31,
	2021		2020
Raw materials and supplies	$	866,963	$	773,021
Work-in-process		100,801		87,159
Finished goods		3,744,029		2,312,148
Total	$	4,711,793	$	3,172,328

Long-lived assets

Property and equipment

	December 31,
	2021			2020
Laboratory and manufacturing equipment	$	4,613,324		$	6,317,340
Office furniture and equipment		810,574			1,259,838
Computers and network equipment		491,183			1,692,154
Leasehold improvements		1,634,692			752,493
		7,549,773			10,021,825
Less accumulated depreciation		(3,538,025	)		(6,762,338	)
Property and equipment, net	$	4,011,748		$	3,259,487

Leases

ROU Assets

Intangible assets and goodwill

Intangible assets and goodwill as of December 31, 2021 consist of finite-lived and indefinite-lived intangible assets and goodwill.

Finite-lived and indefinite-lived intangible assets

Intangible assets include trademarks, developed technology, In-Process Research & Development, software and customer relationships and consisted of the following as of December 31, 2021 and 2020:

					December 31, 2021							December 31, 2020
	Subsidiary		Cost		Accumulated Amortization and Prior Year Impairment			Effect of Foreign Exchange Rates		Net Balance		Accumulated Amortization			Impairment			Effect of Foreign Exchange Rates		Net Balance
Trademarks and tradenames		AdvanDx	$	461,000	$	(461,000	)	$	—	$	—	$	(217,413	)	$	(243,587	)	$	—	$	—
Developed technology		AdvanDx		458,000		(458,000	)		—		—		(308,526	)		(149,474	)		—		—
Customer relationships		AdvanDx		1,094,000		(1,094,000	)		—		—		(736,465	)		(357,535	)		—		—
Trademarks and tradenames		Curetis		1,768,000		(316,930	)		43,015		1,494,085		(147,161	)		—			194,119		1,814,958
Distributor relationships		Curetis		2,362,000		(282,277	)		57,465		2,137,188		(131,070	)		—			259,336		2,490,266
A50 - Developed technology		Curetis		349,000		(89,384	)		8,492		268,108		(41,504	)		—			38,319		345,815
Ares - Developed technology		Curetis		5,333,000		(682,833	)		129,745		4,779,912		(317,060	)		—			585,536		5,601,476
A30 - In-Process Research & Development		Curetis		5,706,000		—			144,916		5,850,916		—			—			622,448		6,328,448
			$	17,531,000	$	(3,384,424	)	$	383,633	$	14,530,209	$	(1,899,199	)	$	(750,596	)	$	1,699,758	$	16,580,963

Identifiable intangible assets will be amortized on a straight-line basis over their estimated useful lives. The estimated useful lives of the intangibles are:

		Estimated Useful Life
Trademarks and tradenames		10 years
Customer/distributor relationships		15 years
A50 – Developed technology		7 years
Ares – Developed technology		14 years
A30 – Acquired in-process research & development		Indefinite

The Company reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.

F-14

Year Ending December 31,
2022	$	783,669
2023		783,669
2024		783,669
2025		783,669
2026		783,669
Thereafter		4,760,948
Total	$	8,679,293

Goodwill

The changes in the carrying amount of goodwill as of December 31, 2021, and since December 31, 2019, were as follows:

Balance as of December 31, 2019	$	600,814
Acquisition of Curetis		6,688,652
Changes in currency translation		735,263
Balance as of December 31, 2020		8,024,729
Changes in currency translation		(571,722	)
Balance as of December 31, 2021	$	7,453,007

Revenue recognition

F-15

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

Government grant agreements and research incentives

Research and development costs, net

Stock-based compensation

Fair value of common stock

The Company uses the quoted market price of its common stock as its fair value.

F-16

Expected volatility

Expected dividend yield

The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.

Risk-free interest rate

This is the U.S. Treasury rate for the day of each option grant during the year, having a term that most closely resembles the expected term of the option.

Expected term

Income taxes

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

F-17

Adopted accounting pronouncements

Recently issued accounting standards

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	36,080,392	$	13,360,463
Restricted cash		551,794		746,792
Total cash and cash equivalents and restricted cash in the consolidated statements of cash flows	$	36,632,186	$	14,107,255

Schedule of Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	December 31,
	2021		2020
Raw materials and supplies	$	866,963	$	773,021
Work-in-process		100,801		87,159
Finished goods		3,744,029		2,312,148
Total	$	4,711,793	$	3,172,328

Schedule of Property and equipment

	December 31,
	2021			2020
Laboratory and manufacturing equipment	$	4,613,324		$	6,317,340
Office furniture and equipment		810,574			1,259,838
Computers and network equipment		491,183			1,692,154
Leasehold improvements		1,634,692			752,493
		7,549,773			10,021,825
Less accumulated depreciation		(3,538,025	)		(6,762,338	)
Property and equipment, net	$	4,011,748		$	3,259,487

Schedule of Finite-Lived and Indefinite-Lived Intangible Assets

Intangible assets include trademarks, developed technology, In-Process Research & Development, software and customer relationships and consisted of the following as of December 31, 2021 and 2020:

					December 31, 2021							December 31, 2020
	Subsidiary		Cost		Accumulated Amortization and Prior Year Impairment			Effect of Foreign Exchange Rates		Net Balance		Accumulated Amortization			Impairment			Effect of Foreign Exchange Rates		Net Balance
Trademarks and tradenames		AdvanDx	$	461,000	$	(461,000	)	$	—	$	—	$	(217,413	)	$	(243,587	)	$	—	$	—
Developed technology		AdvanDx		458,000		(458,000	)		—		—		(308,526	)		(149,474	)		—		—
Customer relationships		AdvanDx		1,094,000		(1,094,000	)		—		—		(736,465	)		(357,535	)		—		—
Trademarks and tradenames		Curetis		1,768,000		(316,930	)		43,015		1,494,085		(147,161	)		—			194,119		1,814,958
Distributor relationships		Curetis		2,362,000		(282,277	)		57,465		2,137,188		(131,070	)		—			259,336		2,490,266
A50 - Developed technology		Curetis		349,000		(89,384	)		8,492		268,108		(41,504	)		—			38,319		345,815
Ares - Developed technology		Curetis		5,333,000		(682,833	)		129,745		4,779,912		(317,060	)		—			585,536		5,601,476
A30 - In-Process Research & Development		Curetis		5,706,000		—			144,916		5,850,916		—			—			622,448		6,328,448
			$	17,531,000	$	(3,384,424	)	$	383,633	$	14,530,209	$	(1,899,199	)	$	(750,596	)	$	1,699,758	$	16,580,963

Schedule of Estimated Useful Lives of Identifiable Intangible Assets

Identifiable intangible assets will be amortized on a straight-line basis over their estimated useful lives. The estimated useful lives of the intangibles are:

		Estimated Useful Life
Trademarks and tradenames		10 years
Customer/distributor relationships		15 years
A50 – Developed technology		7 years
Ares – Developed technology		14 years
A30 – Acquired in-process research & development		Indefinite

Schedule of Expected Amortization of Intangible Assets

Year Ending December 31,
2022	$	783,669
2023		783,669
2024		783,669
2025		783,669
2026		783,669
Thereafter		4,760,948
Total	$	8,679,293

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill as of December 31, 2021, and since December 31, 2019, were as follows:

Balance as of December 31, 2019	$	600,814
Acquisition of Curetis		6,688,652
Changes in currency translation		735,263
Balance as of December 31, 2020		8,024,729
Changes in currency translation		(571,722	)
Balance as of December 31, 2021	$	7,453,007

Business Combination (Tables)

12 Months Ended

Dec. 31, 2021

Business Combinations [Abstract]

Schedule of Components of Purchase Price and Net Assets Acquired

The components of the purchase price and net assets acquired are as follows:

Purchase Price

Number of shares issued to Curetis N.V		2,028,208
Multiplied by the market value per share of OpGen's common stock (i)	$	2.39
Total fair value of common stock issued to Curetis N.V shareholders		4,847,417
Fair value of replacement stock awards related to precombination service (ii)		136,912
Fair value of convertible notes assumed (iii)		1,323,750
Fair value of EIB debt assumed (iv)		15,784,892
Funds advanced to Curetis GmbH under Interim Facility		4,808,712
Cash, cash equivalents, and restricted cash acquired		(1,266,849	)
	$	25,634,834

	(i)			The price per share of OpGen’s common stock was based on the closing price as reported on the Nasdaq Capital Market on April 1, 2020.
	(ii)			The fair value of the stock options assumed was determined using the Black-Scholes option pricing model.
	(iii)			To derive the fair value of the convertible notes, the Company estimated the fair value of the convertible notes with and without the derivative liability using a scenario analysis and Monte Carlo simulation.
	(iv)			The fair value of the EIB debt is determined using a discounted cash flow analysis with current applicable rates for similar instruments.

Schedule of Net Assets Acquired

Net Assets Acquired

Assets acquired
Receivables	$	482,876
Inventory		2,022,577
Property and equipment		3,802,431
Right of use assets		1,090,812
Other current assets		925,364
Finite-lived intangible assets
Trade names/trademarks		1,768,000
Customer/distributor relationships		2,362,000
A50 - Developed technology		349,000
Ares - Developed technology		5,333,000
Indefinite-lived intangible assets
A30 - In-process research & development		5,706,000
Goodwill		6,688,652
Liabilities assumed
Accounts payable		(1,168,839	)
Accrued expenses and other current liabilities		(1,953,927	)
Derivative liabilities		(615,831	)
Lease liabilities		(1,108,193	)
Other long-term liabilities		(49,088	)
Net assets acquired	$	25,634,834

Schedule of Unaudited Pro Forma Results

Unaudited pro forma results	Year ended December 31,
	2020
Revenues	$	5,239,192
Net loss		(29,319,303	)
Net loss per share		(1.86	)

Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Schedule of Revenues by Type of Service

	Years Ended December,
	2021		2020
Product sales	$	2,656,669	$	2,704,364
Laboratory services		813,210		167,736
Collaboration revenue		836,152		1,342,341
Total revenue	$	4,306,031	$	4,214,441

Schedule of Revenues by Geography

Revenues by geography are as follows:

	Years Ended December,
	2021		2020
Domestic	$	1,203,748	$	1,917,367
International		3,102,283		2,297,074
Total revenue	$	4,306,031	$	4,214,441

Summary of Changes in Deferred Revenue

Deferred revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2019	$	9,808
Acquired deferrals from Curetis		829,275
Revenue recognized in the period from amounts acquired from Curetis		(870,114	)
Effect of foreign exchange rates		40,839
Balance at December 31, 2020		9,808
New deferrals, net of amounts recognized in the current period		—
Amounts returned to customers		(9,808	)
Effect of foreign exchange rates		—
Balance at December 31, 2021	$	—

Fair value measurements (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The fair value of level 3 liabilities measured at fair value on a recurring basis for the years ended December 31, 2021 and 2020 was as follows:

Description

Balance at

December 31,

2020

Change in Fair

Value

Effect of Foreign

Exchange Rates

Balance at

December 31,

2021

Participation percentage interest liability

112,852

129,731

(13,994

)

228,589

Total revenue

112,852

129,731

(13,994

)

228,589

Description	Balance at December 31, 2019		Acquired from Curetis		Change in Fair Value			Effect of Foreign Exchange Rates		Balance at December 31, 2020
Participation percentage interest liability	$	—	$	173,373	$	(75,222	)	$	14,701	$	112,852
Embedded conversion option liability		—		442,458		(442,458	)		—		—
Total revenue	$	—	$	615,831	$	(517,680	)	$	14,701	$	112,852

Debt (Tables)

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Abstract]

Schedule of Long-term Debt and Short-term Borrowings

The following table summarizes the Company’s long-term debt and short-term borrowings as December 31, 2021 and 2020:

	December 31,
	2021			2020
EIB	$	25,161,855		$	25,936,928
PPP		—			259,353
MGHIF		—			331,904
Insurance financings		—			107,742
Total debt obligations		25,161,855			26,635,927
Unamortized debt discount		(3,466,491	)		(6,557,992	)
Carrying value of debt		21,695,364			20,077,935
Less current portion		(14,519,113	)		(699,000	)
Long-term debt	$	7,176,251		$	19,378,935

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2021

Stockholders' Equity Note [Abstract]

Schedule of Company Recognized Stock-Based Compensation Expense

For the years ended December 31, 2021 and 2020, the Company recognized stock compensation expense as follows:

	Years Ended December 31,
	2021		2020
Cost of services	$	10,299	$	2,927
Research and development		232,319		62,783
General and administrative		553,557		231,010
Sales and marketing		82,400		19,366
	$	878,575	$	316,086

Schedule of Status of Options Granted

A summary of the status of options granted is presented below as of and for the years ended December 31, 2021 and 2020:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding at December 31, 2019		9,654		$	418.10		8.0	$	—
Granted		1,525,000		$	2.13
Exercised		—		$	—
Assumed in business combination		134,371		$	48.40
Forfeited		(3,631	)	$	21.11
Expired		(872	)	$	473.92
Outstanding at December 31, 2020		1,664,522		$	7.99		9.4	$	—
Granted		415,000		$	1.99
Exercised		—		$	—
Forfeited		(363,554	)	$	2.17
Expired		(2,619	)	$	544.38
Outstanding at December 31, 2021		1,713,349		$	6.88		8.5	$	—
Vested and expected to vest		1,713,349		$	6.88		8.5	$	—
Exercisable at December 31, 2021		731,090		$	10.45		8.0	$	—

Schedule of Fair Value of Option Grant Estimated Using Black-Scholes Option Pricing Model

	Years Ended December 31,
	2021		2020
Annual dividend		—		—
Expected life (in years)		5.75 - 6.00		5.25 - 6.25
Risk free interest rate		0.9% - 1.1%		0.3% - 0.5%
Expected volatility		121.3% - 123.1%		40.9% - 46.6%

Schedule of Status of Restricted Stock Units Granted

A summary of the status of restricted stock units granted is presented below as of and for the years ended December 31, 2021 and 2020:

	Number of Units			Weighted-Average Grant Date Fair Value
Unvested at December 31, 2019		14,975		$	8.76
Granted		—		$	—
Vested		(5,924	)	$	8.51
Forfeited		(933	)	$	8.84
Unvested at December 31, 2020		8,118		$	8.93
Granted		360,000		$	1.99
Vested		(3,768	)	$	8.94
Forfeited		(78,085	)	$	2.23
Unvested at December 31, 2021		286,265		$	2.03

Schedule of Warrants to Purchase Shares of Common Stock

At December 31, 2021 and 2020, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at December 31,
Issuance		Exercise Price	Expiration	2021 (1)	2020 (1)
November 2011	$	3,955.00	November 2021	—	15
December 2011	$	3,955.00	December 2021	—	2
February 2015	$	3,300.00	February 2025	451	451
May 2016	$	656.20	May 2021	—	9,483
June 2016	$	656.20	May 2021	—	4,102
June 2017	$	390.00	June 2022	938	938
July 2017	$	345.00	July 2022	318	318
July 2017	$	250.00	July 2022	2,501	2,501
July 2017	$	212.60	July 2022	50,006	50,006
February 2018	$	81.25	February 2023	9,232	9,232
February 2018	$	65.00	February 2023	92,338	92,338
October 2019	$	2.00	October 2024	354,000	359,000
October 2019	$	2.60	October 2024	235,000	235,000
November 2020	$	1.94	May 2026	—	4,842,615
November 2020	$	2.68	May 2026	242,130	242,130
February 2021	$	3.55	August 2026	4,166,666	—
February 2021	$	3.90	August 2026	416,666	—
March 2021	$	3.56	March 2026	3,147,700	—
October 2021	$	2.05	April 2027	7,500,000	—
				16,217,946	5,848,131

The warrants listed above were issued in connection with various equity, debt, preferred stock or development contract agreements.


(1)	Warrants to purchase fractional shares of common stock resulting from the reverse stock split on August 22, 2019 were rounded up to the next whole share of common stock on a holder by holder basis.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Provision Income Taxes Expense

The Company’s provision for income taxes consists of the following for the years ended December 31, 2021 and 2020:

	December 31,
	2021		2020
Current income tax provision
Federal	$	36,084	$	—
State		7,744		—
Foreign		—		132,403
Total		43,828		132,403
Deferred income tax provision
Federal		—		—
State		—		—
Foreign		—		—
Total		—		—
Total provision for income taxes	$	43,828	$	132,403

Schedule of Deferred Tax Assets and Liabilities

	December 31,
	2021			2020
Deferred tax assets:
NOL carryforward	$	102,388,393		$	98,165,790
R&D credit carryforward		2,559,479			2,559,479
Share-based compensation		498,658			319,397
Depreciation		—			100,157
Interest expense		502,575			1,233,203
ROU liabilities		567,624			475,645
Accruals and other		322,538			331,631
Total deferred tax assets		106,839,267			103,185,302
Valuation allowance		(106,088,316	)		(98,874,420	)
Deferred tax liabilities:
Intangible assets		(178,478	)		(3,885,485	)
ROU assets		(225,057	)		(425,397	)
Depreciation		(347,416	)		—
Net	$	—		$	—

Schedule of Expected Income Tax Provision (Benefit) from Applying Federal Statutory Tax Rates to the Pre-Tax Loss and Actual Income Tax Provision (Benefit)

	2021			2020
Federal income tax benefit at statutory rates		21.0	%		21.0	%
Permanent adjustment		(4.4	)%		0.6	%
Provision to return adjustment		(0.1	)%		—
State income tax benefit, net of federal benefit		1.6	%		3.5	%
Foreign rate differential		2.4	%		2.8	%
Change in valuation allowance		(20.6	)%		(28.4	)%
		(0.1	)%		(0.5	)%

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Schedule of ROU Assets and Lease Liabilities

The following table presents the Company’s ROU assets and lease liabilities as of December 31, 2021 and 2020:

Lease Classification	December 31, 2021		December 31, 2020
ROU Assets:
Operating	$	1,814,396	$	2,082,300
Financing		90,467		449,628
Total ROU assets	$	1,904,863	$	2,531,928
Liabilities
Current:
Operating	$	459,792	$	964,434
Finance		43,150		266,470
Noncurrent:
Operating		2,977,402		1,492,544
Finance		3,644		46,794
Total lease liabilities	$	3,483,988	$	2,770,242

Schedule of Maturities of Lease Liabilities

Maturities of lease liabilities as of December 31, 2021 by year are as follows:

Maturity of Lease Liabilities	Operating			Finance			Total
2022	$	745,850		$	44,850		$	790,700
2023		639,172			3,364			642,536
2024		648,767			280			649,047
2025		544,080			—			544,080
2026		378,279			—			378,279
Thereafter		2,126,371			—			2,126,371
Total lease payments		5,082,519			48,494			5,131,013
Less: Interest		(1,645,325	)		(1,700	)		(1,647,025	)
Present value of lease liabilities	$	3,437,194		$	46,794		$	3,483,988

Schedule of Statement of Operations Classification of Lease Costs and Other Information

Consolidated statements of operations classification of lease costs as of the years ended December 31, 2021 and 2020 are as follows:

		Years ended December 31,
Lease Cost	Classification	2021		2020
Operating	Operating expenses	$	1,055,595	$	1,205,551
Finance:
Amortization	Operating expenses		359,162		508,962
Interest expense	Other expenses		15,481		57,247
Total lease costs		$	1,430,238	$	1,771,760

Other lease information as of December 31, 2021 is as follows:

Other Information	Total
Weighted average remaining lease term (in years)
Operating leases		7.6
Finance leases		0.9
Weighted average discount rate:
Operating leases		8.9	%
Finance leases		9.1	%

Schedule of Supplemental Cash Flow Information

Supplemental cash flow information for the years ended December 31, 2021, and 2020 is as follows:

Supplemental Cash Flow Information	2021		2020
Cash paid for amounts included in the measurement of lease liabilities
Cash used in operating activities
Operating leases	$	1,055,595	$	1,205,551
Finance leases	$	15,481	$	57,247
Cash used in financing activities
Finance leases	$	266,470	$	579,029
ROU assets obtained in exchange for lease obligations:
Operating leases	$	615,761	$	1,008,039
Finance leases	$	—	$	—

Going Concern and Management's Plans (Details) - USD ($)				1 Months Ended		12 Months Ended
	Dec. 08, 2021	Mar. 09, 2021	Feb. 11, 2021	Oct. 18, 2021	Nov. 25, 2020	Dec. 31, 2021	Dec. 31, 2020	Feb. 11, 2020
Conversion of Stock [Line Items]
Preferred Stock, Par or Stated Value Per Share						$ 0.01	$ 0.01
Proceeds from issuance of common stock, net of issuance costs						$ 1,483,833	$ 15,821,922
Common Stock [Member] \| 2020 ATM Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues						680,000	7,521,610
Gross proceeds from sale of common stock						$ 1,550,000	$ 16,700,000
Proceeds from issuance of common stock, net of issuance costs						$ 1,480,000	$ 15,800,000
Common Stock [Member] \| 2020 ATM Offering [Member] \| Maximum [Member]
Conversion of Stock [Line Items]
Common shares available for future issuance amount								$ 22,100,000
Warrants [Member]
Conversion of Stock [Line Items]
Proceeds from issuance of warrant		$ 9,650,000
October 2021 Offering [Member]
Conversion of Stock [Line Items]
Convertible preferred stock	7,500,000			7,500,000		7,500,000
Stock issued during period, shares, new issues	150,000			150,000
Preferred Stock, Par or Stated Value Per Share				$ 100
Conversion preferred stock per share				$ 2.00
Gross proceeds from sale of common stock				$ 15,000,000.0
Proceeds from issuance of common stock, net of issuance costs				$ 13,900,000
Class of warrant or right, exercise price of warrants or rights				$ 2.05
Warrants exercisable period				6 months
Warrants expiry period				5 years
October 2021 Offering [Member] \| Warrants [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues				7,500,000
Purchase Agreement [Member] \| Warrant [Member]
Conversion of Stock [Line Items]
Cash fee compensation		$ 200,000
Exercise Agreement [Member] \| Warrant [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights		$ 3.56
Warrants expiry period		5 years
Number of each warrant issue to purchase common stock		0.65
New warrants issue against outstanding warrants		3,147,700
Payment to purchase new warrants		$ 255,751
February 2021 Offering [Member]
Conversion of Stock [Line Items]
Offering of common stock and warrants			4,166,666
Stock issued during period, shares, new issues			2,784,184
Shares issued, price per share			$ 3.00
Gross proceeds from sale of common stock			$ 25,000,000.0
Proceeds from issuance of common stock, net of issuance costs			$ 23,500,000
Sale of stock, description of transaction			each pre-funded warrant exercisable for one share of common stock
Class of warrant or right, exercise price of warrants or rights			$ 3.55
Warrants exercisable period			6 months
Warrants expiry period			5 years 6 months
February 2021 Offering [Member] \| Pre Funded Warrant [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues			5,549,149			5,549,149
Shares issued, price per share			$ 2.99
Sale of stock, description of transaction						each pre-funded warrant exercisable for one share of common stock.
Class of warrant or right, exercise price of warrants or rights			$ 0.01
Warrants exercised			4,166,666
2020 PIPE [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues					2,245,400
Shares issued, price per share					$ 2.065
Gross proceeds from sale of common stock					$ 10,000,000.0
Proceeds from issuance of common stock, net of issuance costs					$ 9,300,000
Sale of stock, description of transaction					with each pre-funded warrant exercisable for one share of common stock
Class of warrant or right, exercise price of warrants or rights					$ 1.94
Warrants exercisable period					6 months
Warrants exercised		4,842,615			4,842,615
Warrants expiry period					5 years 6 months
New warrants issue against outstanding warrants					2,245,400
2020 PIPE [Member] \| Maximum [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues					2,245,400
2020 PIPE [Member] \| Pre Funded Warrant [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues					2,597,215
Shares issued, price per share					$ 2.055
Sale of stock, description of transaction						each pre-funded warrant exercisable for one share of common stock
Warrants exercised					2,597,215
New warrants issue against outstanding warrants					2,597,215		2,597,215

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Significant Accounting Policies [Line Items]
FDIC limit of insurable cash	$ 250,000
Letters of credit outstanding, amount	551,794	$ 746,792
Allowance for doubtful accounts receivable	0	20,753
Inventory valuation reserves	98,064	288,378
Amortization of intangible assets	813,184	672,823
Impairment of finite-lived intangible assets		750,596
Share-based compensation arrangement by share-based payment award, award vesting period	4 years
Goodwill	$ 7,453,007	$ 8,024,729	$ 600,814
Finite-lived intangible assets, fair value	$ 0
Antidilutive securities excluded from computation of earnings per share, amount	18.2	7.5
Depreciation expense	$ 1,541,561	$ 1,152,954
Research and development expense to government grant	692,701	495,153
Earned but not yet received	396,365	413,530
Domestic Country [Member]
Significant Accounting Policies [Line Items]
Operating loss carryforwards	$ 202,015,062	196,511,928
Operating loss carryforwards, expiration terms	begin to expire in 2022
Foreign [Member]
Significant Accounting Policies [Line Items]
Operating loss carryforwards	$ 170,607,782
Operating loss carryforwards, foreign subsidiaries	147,313,786
ASU 2016-02 [Member]
Significant Accounting Policies [Line Items]
Impairment charge	$ 170,714	$ 101,838
Customer Two [Member] \| Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	13.00%
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage		20.00%
Customer One [Member] \| Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	15.00%	21.00%
Customer Three [Member] \| Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	12.00%
Minimum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due	30 days
Fair value assumptions, expected term	5 years 9 months	5 years 3 months
Minimum [Member] \| Employee Stock Option [Member]
Significant Accounting Policies [Line Items]
Fair value assumptions, expected term	6 years 3 months
Minimum [Member] \| Customer Two [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	52.00%
Maximum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due	60 days
Fair value assumptions, expected term	6 years	6 years 3 months
Maximum [Member] \| Employee Stock Option [Member]
Significant Accounting Policies [Line Items]
Fair value assumptions, expected term	10 years
Maximum [Member] \| Customer Two [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	14.00%

Summary of Significant Accounting Policies (Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 36,080,392	$ 13,360,463
Restricted cash	551,794	746,792
Total cash and cash equivalents and restricted cash in the consolidated statements of cash flows	$ 36,632,186	$ 14,107,255

Summary of Significant Accounting Policies (Schedule of Inventories) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventories
Raw materials and supplies	$ 866,963	$ 773,021
Work-in-process	100,801	87,159
Finished goods	3,744,029	2,312,148
Total	$ 4,711,793	$ 3,172,328

Summary of Significant Accounting Policies (Schedule of Property and equipment) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property and equipment, Gross	$ 7,549,773	$ 10,021,825
Less accumulated depreciation	(3,538,025)	(6,762,338)
Property and equipment, net	4,011,748	3,259,487
Laboratory and manufacturing equipment [Member]
Property and equipment, Gross	4,613,324	6,317,340
Office furniture and equipment [Member]
Property and equipment, Gross	810,574	1,259,838
Computers and network equipment [Member]
Property and equipment, Gross	491,183	1,692,154
Leasehold improvements [Member]
Property and equipment, Gross	$ 1,634,692	$ 752,493

Summary of Significant Accounting Policies (Schedule of Finite-Lived and Indefinite-Lived Intangible Assets) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Cost	$ 17,531,000	$ 17,531,000
Accumulated Amortization		(1,899,199)
Impairment		(750,596)
Accumulated Amortization and Prior Year Impairment	(3,384,424)
Effect of foreign exchange rates	383,633	1,699,758
Net Balance	14,530,209	16,580,963
Trademarks and tradenames [Member] \| AdvanDx [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	461,000	461,000
Accumulated Amortization		(217,413)
Impairment		(243,587)
Accumulated Amortization and Prior Year Impairment	(461,000)
Effect of foreign exchange rates
Net Balance
Trademarks and tradenames [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,768,000	1,768,000
Accumulated Amortization		(147,161)
Impairment
Accumulated Amortization and Prior Year Impairment	(316,930)
Effect of foreign exchange rates	43,015	194,119
Net Balance	1,494,085	1,814,958
Developed Technology [Member] \| AdvanDx [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	458,000	458,000
Accumulated Amortization		(308,526)
Impairment		(149,474)
Accumulated Amortization and Prior Year Impairment	(458,000)
Effect of foreign exchange rates
Net Balance
Customer/distributor relationships [Member] \| AdvanDx [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,094,000	1,094,000
Accumulated Amortization		(736,465)
Impairment		(357,535)
Accumulated Amortization and Prior Year Impairment	(1,094,000)
Effect of foreign exchange rates
Net Balance
Distributor Relationships [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	2,362,000	2,362,000
Accumulated Amortization		(131,070)
Impairment
Accumulated Amortization and Prior Year Impairment	(282,277)
Effect of foreign exchange rates	57,465	259,336
Net Balance	2,137,188	2,490,266
A50 - Developed technology [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	349,000	349,000
Accumulated Amortization		(41,504)
Impairment
Accumulated Amortization and Prior Year Impairment	(89,384)
Effect of foreign exchange rates	8,492	38,319
Net Balance	268,108	345,815
Ares - Developed technology [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	5,333,000	5,333,000
Accumulated Amortization		(317,060)
Impairment
Accumulated Amortization and Prior Year Impairment	(682,833)
Effect of foreign exchange rates	129,745	585,536
Net Balance	4,779,912	5,601,476
A30 - Acquired in-process research & development [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	5,706,000	5,706,000
Accumulated Amortization
Impairment
Accumulated Amortization and Prior Year Impairment
Effect of foreign exchange rates	144,916	622,448
Net Balance	$ 5,850,916	$ 6,328,448

Summary of Significant Accounting Policies (Schedule of Estimated Useful Lives of Identifiable Intangible Assets) (Details)	12 Months Ended
	Dec. 31, 2021
A50 - Developed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	7 years
Ares - Developed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	14 years
A30 - Acquired in-process research & development [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	Indefinite
Trademarks and tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	10 years
Customer/distributor relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	15 years

Summary of Significant Accounting Policies (Schedule of Expected Amortization of Intangible Assets) (Details)	Dec. 31, 2021 USD ($)
Accounting Policies [Abstract]
2022	$ 783,669
2023	783,669
2024	783,669
2025	783,669
2026	783,669
Thereafter	4,760,948
Total	$ 8,679,293

Summary of Significant Accounting Policies (Schedule of Changes in Carrying Amount of Goodwill) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Balance as of December 31, 2020	$ 8,024,729	$ 600,814
Acquisition of Curetis		6,688,652
Changes in currency translation	(571,722)	735,263
Balance as of December 31, 2021	$ 7,453,007	$ 8,024,729

Business Combination (Narrative) (Details)	12 Months Ended
Business Combination (Narrative) (Details)	Dec. 31, 2021 shares
Customer/distributor relationships [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	15 years
Trademarks and tradenames [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	10 years
Curetis N.V [Member] \| Customer/distributor relationships [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	15 years
Curetis N.V [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	10 years
Curetis N.V [Member] \| Trademarks and tradenames [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	10 years
Curetis N.V [Member] \| 2016 Stock Option Plan [Member]
Business Acquisition [Line Items]
Common stock reserved for future issuance	134,356
Common stock to be issued upon conversion	500,000

Business Combination (Schedule of Components of Purchase Price and Net Assets Acquired) (Details) - Curetis N.V [Member]

12 Months Ended

Dec. 31, 2021

USD ($)

$ / shares

Purchase Price

Number of shares issued to Curetis N.V | shares

2,028,208

Multiplied by the market value per share of OpGen's common stock | $ / shares

$ 2.39

^[1]

Total fair value of common stock issued to Curetis N.V shareholders

$ 4,847,417

Fair value of replacement stock awards related to precombination service

136,912

^[2]

Fair value of convertible notes assumed

1,323,750

^[3]

Fair value of EIB debt assumed

15,784,892

^[4]

Funds advanced to Curetis GmbH under Interim Facility

4,808,712

Cash, cash equivalents, and restricted cash acquired

(1,266,849)

Purchase Price

$ 25,634,834

[1]	The price per share of OpGen’s common stock was based on the closing price as reported on the Nasdaq Capital Market on April 1, 2020.
[2]	The fair value of the stock options assumed was determined using the Black-Scholes option pricing model.
[3]	To derive the fair value of the convertible notes, the Company estimated the fair value of the convertible notes with and without the derivative liability using a scenario analysis and Monte Carlo simulation.
[4]	The fair value of the EIB debt is determined using a discounted cash flow analysis with current applicable rates for similar instruments.

Business Combination (Schedule of Net Assets Acquired) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Assets acquired
Goodwill	$ 7,453,007	$ 8,024,729	$ 600,814
Curetis N.V [Member]
Assets acquired
Receivables	482,876
Inventory	2,022,577
Property and equipment	3,802,431
Right of use assets	1,090,812
Other current assets	925,364
Goodwill	6,688,652
Liabilities assumed
Accounts payable	(1,168,839)
Accrued expenses and other current liabilities	(1,953,927)
Derivative liabilities	(615,831)
Lease liabilities	(1,108,193)
Other long-term liabilities	(49,088)
Net assets acquired	25,634,834
Curetis N.V [Member] \| Trademarks and tradenames [Member]
Assets acquired
Finite-lived intangible assets	1,768,000
Curetis N.V [Member] \| Customer/distributor relationships [Member]
Assets acquired
Finite-lived intangible assets	2,362,000
Curetis N.V [Member] \| A50 - Developed technology [Member]
Assets acquired
Finite-lived intangible assets	349,000
Curetis N.V [Member] \| Ares - Developed technology [Member]
Assets acquired
Finite-lived intangible assets	5,333,000
Curetis N.V [Member] \| A30 - Acquired in-process research & development [Member]
Assets acquired
Indefinite-lived intangible assets	$ 5,706,000

Business Combination (Schedule of Unaudited Pro Forma Results) (Details) - Curetis N.V [Member]	12 Months Ended
	Dec. 31, 2020 USD ($) $ / shares
Business Acquisition [Line Items]
Revenues	$ 5,239,192
Net loss	$ (29,319,303)
Net loss per share \| $ / shares	$ (1.86)

Revenue from contracts with customers (Narrative) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract assets	$ 0	$ 18,000

Revenue from contracts with customers (Schedule of Revenues by Type of Service) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 4,306,031	$ 4,214,441
Product sales [Member]
Disaggregation of Revenue [Line Items]
Total revenue	2,656,669	2,704,364
Laboratory services [Member]
Disaggregation of Revenue [Line Items]
Total revenue	813,210	167,736
Collaborations Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 836,152	$ 1,342,341

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue from contracts with customers (Schedule of Revenues by Geography) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 4,306,031	$ 4,214,441
Domestic [Member]
Disaggregation of Revenue [Line Items]
Total revenue	1,203,748	1,917,367
International [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 3,102,283	$ 2,297,074

- Definition

+ References

+ Details

Revenue from contracts with customers (Summary of Changes in Deferred Revenue) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue Recognition and Deferred Revenue [Abstract]
Balance at December 31, 2020	$ 9,808	$ 9,808
Acquired deferrals from Curetis		829,275
Revenue recognized in the period from the amounts acquired from Curetis		(870,114)
Effect of foreign exchange rates		40,839
New deferrals, net of amounts recognized in the current period
Amounts returned to customers	(9,808)
Balance at December 31, 2021		$ 9,808

Fair value measurements (Narrative) (Details) € in Millions	1 Months Ended	12 Months Ended
Fair value measurements (Narrative) (Details) € in Millions	Jun. 30, 2019 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of right-of-use asset		$ 170,714	$ 101,838
Fair Value on Non-Recurring Basis [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of non-financial assets and liabilities at fair value			750,596
Impairment of right-of-use asset		$ 170,714	$ 101,838
Fair Value on Recurring Basis [Member] \| Curetis GmbH [Member] \| European Investment Bank [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Drew down amount \| €	€ 5.0
Participation percentage interest	2.10%
Additional payment percentage	2.10%
Fair Value on Recurring Basis [Member] \| Curetis GmbH [Member] \| European Investment Bank [Member] \| Share-based Payment Arrangement, Tranche One [Member] \| Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cumulative equity capital raised \| €	€ 15.0
Fair Value on Recurring Basis [Member] \| OpGen's Equity [Member] \| European Investment Bank [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Participation percentage interest	0.30%
Maturity period		mid-2024 and mid-2025

Fair value measurements (Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period	$ 112,852
Acquired from Curetis		615,831
Change in Fair Value	129,731	(517,680)
Effect of Foreign Exchange Rates	(13,994)	14,701
Balance at the end of the period	228,589	112,852
Participation percentage interest liability [Member]
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period	112,852
Acquired from Curetis		173,373
Change in Fair Value	129,731	(75,222)
Effect of Foreign Exchange Rates	(13,994)	14,701
Balance at the end of the period	228,589	112,852
Embedded conversion option liability [Member]
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period
Acquired from Curetis		442,458
Change in Fair Value		(442,458)
Effect of Foreign Exchange Rates
Balance at the end of the period

Debt (Narrative) (Details)				1 Months Ended					12 Months Ended
Debt (Narrative) (Details)	Jul. 10, 2020 EUR (€)	Jun. 11, 2018 USD ($)	Jun. 11, 2018 USD ($)	Jun. 17, 2020 shares	Feb. 24, 2020 $ / shares shares	Jun. 30, 2019 EUR (€)	Jun. 28, 2017 shares	Jul. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2021 EUR (€) shares	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2016 EUR (€)	Dec. 31, 2021 EUR (€)	Dec. 31, 2020 EUR (€)	Jul. 10, 2020 USD ($)	Jul. 09, 2020 EUR (€)	Apr. 22, 2020 USD ($)	Jun. 30, 2018 EUR (€)	Apr. 30, 2017 EUR (€)
Common Stock And Note Purchase Agreement [Line Items]
Proceeds from issuance of common stock, net of issuance costs									$ 1,483,833		$ 15,821,922
Common stock, par value \| $ / shares									$ 0.01		$ 0.01
EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Fund drawn period												36 months
Debt term												5 years
Percentage of participation percentage interest						2.10%
Fair value of debt															$ 15,800,000
Amount of outstanding borrowings									$ 25,161,855
Deferred interest payable									$ 4,775,055
EIB debt financing facility [Member]
Common Stock And Note Purchase Agreement [Line Items]
Defer total interest payments \| €	€ 720,000
PPP [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, face amount																	$ 879,630
Percentage of interest accrues									1.00%	1.00%
Interest expense									$ 4,799,331		$ 3,399,984
PPP [Member] \| Subsidiary Note [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, face amount																	$ 259,353
Euro [Member] \| EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €												€ 25,000,000
Amount of cumulative equity capital raised \| €						€ 15,000,000
Amount of outstanding borrowings \| €										€ 22,216,012
Deferred interest payable \| €													€ 4,216,012
Common Stock [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues \| shares									680,000	680,000	7,521,610
MGHIF Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues \| shares								2,273
Shares issued, price per share \| $ / shares								$ 2,200
Proceeds from issuance of common stock, net of issuance costs								$ 5,000,000.0
Debt instrument, interest rate, stated percentage								8.00%
Debt instrument, face amount								$ 1,000,000.0
Debt term								2 years
MGHIF Financing Agreement [Member] \| Second Amended and Restated Senior Secured Promissory Note [Member]
Common Stock And Note Purchase Agreement [Line Items]
Revised and extended the maturity date, payment terms									six semi-annual payments	six semi-annual payments
Annual payments plus accrued and unpaid interest		$ 166,667	$ 166,667
Beginning date of debt maturity			Jan. 02, 2019
Ending date of debt maturity			Jul. 01, 2021
Unamortized debt issuance costs		7,000	$ 7,000
MGHIF Financing Agreement [Member] \| Private Placement [Member] \| Common Stock [Member] \| Second Amended and Restated Senior Secured Promissory Note [Member]
Common Stock And Note Purchase Agreement [Line Items]
Accrued and unpaid interest		$ 285,512
Accrued and unpaid interest due date		Jul. 14, 2018
Amended and Restated MGHIF Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage							10.00%
Debt instrument, extended maturity date							Jul. 14, 2018
Issuance of common stock warrants to purchase \| shares							656
Assignment Agreement [Member] \| Convertible Note [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues \| shares											763,905
Proceeds from issuance of common stock, net of issuance costs											$ 1,451,000
Common stock, par value \| $ / shares					$ 0.01
Issuance of convertible notes \| shares				450,000	500,000
Fair value of Convertible notes											$ 1,300,000
Assignment Agreement [Member] \| Convertible Note [Member] \| Euro [Member]
Common Stock And Note Purchase Agreement [Line Items]
Unconverted Convertible Notes \| €														€ 1,300,000
First Tranche [Member] \| EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage																			6.00%
Interst rate									EURIBOR plus 4% payable	EURIBOR plus 4% payable
First Tranche [Member] \| Euro [Member] \| EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €																			€ 10,000,000
Second Tranche [Member] \| Euro [Member] \| EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €																		€ 3,000,000
Third Tranche [Member] \| Euro [Member] \| EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €						€ 5,000,000										€ 5,000,000
OpGen's equity value [Member] \| EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Percentage of participation percentage interest						0.30%

Debt (Schedule of Long-term Debt and Short-term Borrowings) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total debt obligations	$ 25,161,855	$ 26,635,927
Unamortized debt discount	(3,466,491)	(6,557,992)
Carrying value of debt	21,695,364	20,077,935
Less current portion	(14,519,113)	(699,000)
Long-term debt	7,176,251	19,378,935
EIB [Member]
Debt Instrument [Line Items]
Total debt obligations	25,161,855	25,936,928
PPP [Member]
Debt Instrument [Line Items]
Total debt obligations		259,353
MGHIF [Member]
Debt Instrument [Line Items]
Total debt obligations		331,904
Insurance financings [Member]
Debt Instrument [Line Items]
Total debt obligations		$ 107,742

Stockholders' Equity (Narrative) (Details) - USD ($)					1 Months Ended			9 Months Ended	12 Months Ended
Stockholders' Equity (Narrative) (Details) - USD ($)	Dec. 08, 2021	Mar. 09, 2021	Feb. 11, 2021	Apr. 01, 2020	Oct. 18, 2021	Nov. 25, 2020	Oct. 28, 2019	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Feb. 11, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized	100,000,000								100,000,000	50,000,000
Common stock, shares issued									46,450,250	25,085,534
Common stock, shares outstanding									46,450,250	25,085,534
Preferred stock, shares authorized									10,000,000	10,000,000
Preferred stock, shares issued									0	0
Preferred stock, shares outstanding									0	0
Proceeds from issuance of common stock, net of issuance costs									$ 1,483,833	$ 15,821,922
Stock options, granted									415,000	1,525,000
Share-based compensation, tax benefit from compensation expense									$ 1,000,000.0
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, period for recognition									2 years 6 months
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value									$ 622,757	$ 549,341
Preferred Stock, Par or Stated Value Per Share									$ 0.01	$ 0.01
Deemed dividend on beneficial conversion feature									$ 7,166,752
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, period for recognition									1 year
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, total									$ 320,000
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized									2,710
Share-based compensation arrangement by share-based payment award, description									the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.
Share-based compensation arrangement by share-based payment award, number of shares available for grant									465,586
Share-based compensation arrangement by share-based payment award, common stock percentage									4.00%
2020 Stock Options Plan [Member] \| ExecutiveOfficers And Non-Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for future issuance, shares								1,300,000
Stock issued during period, shares, new issues								1,300,000
Stock options, granted								1,300,000
2016 Stock Option Plan [Member] \| Replacement Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options awarded										$ 1.68
Number of share options granted										134,371
Curetis GmbH [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Acquisition of shares				2,028,208
Common Stock [Member] \| 2020 ATM Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues									680,000	7,521,610
Proceeds from issuance of common stock, net of issuance costs									$ 1,480,000	$ 15,800,000
Gross proceeds from sale of common stock									1,550,000	16,700,000
Remaining availability under market offering									3,900,000
Common Stock [Member] \| 2020 ATM Offering [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for future issuance amount											$ 22,100,000
New Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of each warrant issue to purchase common stock		0.65
Class of warrant or right, exercise price of warrants or rights		$ 3.56
Issuance of common stock warrants to purchase		3,147,700
Warrants expiry period		5 years
Payment to purchase new warrants		$ 255,751
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of warrant		9,650,000
Non-cash warrant inducement expense		$ 7,800,000
October 2019 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues							2,590,170
Shares issued, price per share							$ 2.00
October 2019 Public Offering [Member] \| Common Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock, net of issuance costs									$ 10,000	$ 8,700,000
Warrants exercised									5,000	4,341,000
October 2019 Public Offering [Member] \| Pre-funded Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues							2,109,830
Shares issued, price per share							$ 1.99
Gross proceeds from sale of common stock and warrants							$ 9,400,000
Net proceeds from sale of common stock and warrants							$ 8,300,000
2020 PIPE [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues						2,245,400
Proceeds from issuance of common stock, net of issuance costs						$ 9,300,000
Gross proceeds from sale of common stock						$ 10,000,000.0
Shares issued, price per share						$ 2.065
Class of warrant or right, exercise price of warrants or rights						$ 1.94
Warrants exercisable period						6 months
Warrants exercised		4,842,615				4,842,615
Issuance of common stock warrants to purchase						2,245,400
Warrants expiry period						5 years 6 months
Sale of stock, description of transaction						with each pre-funded warrant exercisable for one share of common stock
2020 PIPE [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues						2,245,400
2020 PIPE [Member] \| Pre Funded Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues						2,597,215
Shares issued, price per share						$ 2.055
Warrants exercised						2,597,215
Issuance of common stock warrants to purchase						2,597,215				2,597,215
Sale of stock, description of transaction									each pre-funded warrant exercisable for one share of common stock
February 2021 Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues			2,784,184
Proceeds from issuance of common stock, net of issuance costs			$ 23,500,000
Gross proceeds from sale of common stock			$ 25,000,000.0
Shares issued, price per share			$ 3.00
Class of warrant or right, exercise price of warrants or rights			$ 3.55
Warrants exercisable period			6 months
Warrants expiry period			5 years 6 months
Sale of stock, description of transaction			each pre-funded warrant exercisable for one share of common stock
February 2021 Offering [Member] \| Pre Funded Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues			5,549,149						5,549,149
Shares issued, price per share			$ 2.99
Class of warrant or right, exercise price of warrants or rights			$ 0.01
Warrants exercised			4,166,666
Sale of stock, description of transaction									each pre-funded warrant exercisable for one share of common stock.
October 2021 Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues	150,000				150,000
Proceeds from issuance of common stock, net of issuance costs					$ 13,900,000
Gross proceeds from sale of common stock					$ 15,000,000.0
Class of warrant or right, exercise price of warrants or rights					$ 2.05
Warrants exercisable period					6 months
Warrants expiry period					5 years
Preferred Stock, Par or Stated Value Per Share					$ 100
Conversion preferred stock per share					$ 2.00
Convertible preferred stock	7,500,000				7,500,000				7,500,000
October 2021 Offering [Member] \| Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues					7,500,000

Stockholders' Equity (Schedule of Company Recognized Stock-Based Compensation Expense) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 878,575	$ 316,086
Cost of Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	10,299	2,927
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	232,319	62,783
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	553,557	231,010
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 82,400	$ 19,366

Stockholders' Equity (Schedule of Status of Options Granted) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Number of Options, Outstanding Balance	1,664,522	9,654
Number of Options, Granted	415,000	1,525,000
Number of Options, Exercised
Number of Options, Assumed in business combination		134,371
Number of Options, Forfeited	(363,554)	(3,631)
Number of Options, Expired	(2,619)	(872)
Number of Options, Outstanding Balance	1,713,349	1,664,522	9,654
Number of Options, Vested and expected to vest	1,713,349
Number of Options, Exercisable	731,090
Weighted Average Exercise Price, Outstanding Balance	$ 7.99	$ 418.10
Weighted Average Exercise Price, Granted	1.99	2.13
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Assumed in business combination		48.40
Weighted Average Exercise Price, Forfeited	2.17	21.11
Weighted Average Exercise Price, Expired	544.38	473.92
Weighted Average Exercise Price, Outstanding Balance	6.88	$ 7.99	$ 418.10
Weighted Average Exercise Price, Vested and expected to vest	6.88
Weighted Average Exercise Price, Exercisable	$ 10.45
Weighted-Average Remaining Contractual Life, Outstanding (in years)	8 years 6 months	9 years 4 months 24 days	8 years
Weighted-Average Remaining Contractual Life, Vested and expected to vest (in years)	8 years 6 months
Weighted-Average Remaining Contractual Life, Exercisable (in years)	8 years
Aggregate Intrinsic Value, Outstanding
Aggregate Intrinsic Value, Outstanding
Aggregate Intrinsic Value, Vested and expected to vest
Aggregate Intrinsic Value, Exercisable

Stockholders' Equity (Schedule of Fair Value of Option Grant Estimated Using Black-Scholes Option Pricing Model) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual dividend
Risk free interest rate, minimum	0.90%	0.30%
Risk free interest rate, maximum	1.10%	0.50%
Expected volatility, minimum	121.30%	40.90%
Expected volatility, maximum	123.10%	46.60%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	5 years 9 months	5 years 3 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 years	6 years 3 months

Stockholders' Equity (Schedule of Status of Restricted Stock Units Granted) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Number of Options, Outstanding Balance	8,118	14,975
Number of Options, Granted	360,000
Number of Options, Vested	(3,768)	(5,924)
Number of Options, Forfeited	(78,085)	(933)
Number of Options, Outstanding Balance	286,265	8,118
Weighted Average Grant Date Fair Value, Outstanding Balance	$ 8.93	$ 8.76
Weighted Average Grant Date Fair Value, Granted	1.99
Weighted Average Grant Date Fair Value, Vested	8.94	8.51
Weighted Average Grant Date Fair Value, Forfeited	2.23	8.84
Weighted Average Grant Date Fair Value, Outstanding Balance	$ 2.03	$ 8.93

Stockholders' Equity (Warrants to Purchase Shares of Common Stock) (Details) - $ / shares

12 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares of Common Stock Subject to Warrants

^[1]

16,217,946

5,848,131

November 2011 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 3,955.00

Expiration

2021-11

Shares of Common Stock Subject to Warrants

^[1]

December 2011 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 3,955.00

Expiration

2021-12

Shares of Common Stock Subject to Warrants

^[1]

February 2015 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 3,300.00

Expiration

2025-02

Shares of Common Stock Subject to Warrants

^[1]

451

May 2016 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 656.20

Expiration

2021-05

Shares of Common Stock Subject to Warrants

^[1]

9,483

June 2016 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 656.20

Expiration

2021-05

Shares of Common Stock Subject to Warrants

^[1]

4,102

June 2017 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 390.00

Expiration

2022-06

Shares of Common Stock Subject to Warrants

^[1]

938

July 2017 [Member] | Warrants Exercise Price One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 345.00

Expiration

2022-07

Shares of Common Stock Subject to Warrants

^[1]

318

July 2017 [Member] | Warrants Exercise Price Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 250.00

Expiration

2022-07

Shares of Common Stock Subject to Warrants

^[1]

2,501

July 2017 [Member] | Warrants Exercise Price Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 212.60

Expiration

2022-07

Shares of Common Stock Subject to Warrants

^[1]

50,006

February 2018 [Member] | Warrants Exercise Price Four [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 81.25

Expiration

2023-02

Shares of Common Stock Subject to Warrants

^[1]

9,232

February 2018 [Member] | Warrants Exercise Price Five [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 65.00

Expiration

2023-02

Shares of Common Stock Subject to Warrants

^[1]

92,338

October 2019 [Member] | Warrants Exercise Price Six [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 2.00

Expiration

2024-10

Shares of Common Stock Subject to Warrants

^[1]

354,000

359,000

October 2019 [Member] | Warrants Exercise Price Seven [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 2.60

Expiration

2024-10

Shares of Common Stock Subject to Warrants

^[1]

235,000

November 2020 [Member] | Warrants Exercise Price Eight [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 1.94

Expiration

2026-05

Shares of Common Stock Subject to Warrants

^[1]

4,842,615

November 2020 [Member] | Warrants Exercise Price Nine [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 2.68

Expiration

2026-05

Shares of Common Stock Subject to Warrants

^[1]

242,130

February 2021 [Member] | Warrants Exercise Price Ten [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 3.55

Expiration

2026-08

Shares of Common Stock Subject to Warrants

4,166,666

^[1]

February 2021 [Member] | Warrants Exercise Price Eleven [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 3.90

Expiration

2026-08

Shares of Common Stock Subject to Warrants

416,666

^[1]

March 2021 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 3.56

Expiration

2026-03

Shares of Common Stock Subject to Warrants

3,147,700

^[1]

October 2021 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price

$ 2.05

Expiration

2027-04

Shares of Common Stock Subject to Warrants

7,500,000

^[1]

[1]	Warrants to purchase fractional shares of common stock resulting from the reverse stock split on August 22, 2019 were rounded up to the next whole share of common stock on a holder by holder basis.

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax [Line Items]
Loss before income taxes	$ 34,800,000	$ 26,100,000
Net deferred tax assets	106,839,267	103,185,302
Deferred tax assets, valuation allowance	$ 106,088,316	98,874,420
Maximum percentage of taxable income in which NOLs permitted to deduct	80.00%
Domestic Country [Member]
Income Tax [Line Items]
Operating loss carryforwards	$ 202,015,062	$ 196,511,928
Operating loss carryforwards incurred prior to 2018, expiration terms	begin to expire in 2022
Foreign [Member]
Income Tax [Line Items]
Operating loss carryforwards	$ 170,607,782

Income Taxes (Schedule of Provision for Income Taxes) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current income tax provision	$ 43,828	$ 132,403
Deferred income tax provision
Total provision for income taxes	43,828	132,403
Domestic Country [Member]
Current income tax provision	36,084
Deferred income tax provision
State [Member]
Current income tax provision	7,744
Deferred income tax provision
Foreign [Member]
Current income tax provision		132,403
Deferred income tax provision

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
NOL carryforward	$ 102,388,393	$ 98,165,790
R&D credit carryforward	2,559,479	2,559,479
Share-based compensation	498,658	319,397
Depreciation		100,157
Interest expense	502,575	1,233,203
ROU liabilities	567,624	475,645
Accruals and other	322,538	331,631
Total deferred tax assets	106,839,267	103,185,302
Valuation allowance	(106,088,316)	(98,874,420)
Deferred tax liabilities:
Intangible assets	(178,478)	(3,885,485)
ROU assets	(225,057)	(425,397)
Depreciation	(347,416)
Net

Income Taxes (Schedule of Federal Statutory Tax Rates to the Pre-Tax Loss and Actual Income Tax Provision (Benefit)) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rates	21.00%	21.00%
Permanent adjustment	(4.40%)	0.60%
Provision to return adjustment	(0.10%)
State income tax benefit, net of federal benefit	1.60%	3.50%
Foreign rate differential	2.40%	2.80%
Change in valuation allowance	(20.60%)	(28.40%)
Total	(0.10%)	(0.50%)

Commitments and Contingencies (Details) $ in Millions	12 Months Ended
Commitments and Contingencies (Details) $ in Millions	Dec. 31, 2021 USD ($)
Life Technologies Corporation Supply Agreement [Member] \| Quant Studio Five Real Time PCR Systems [Member]
Other Commitments [Line Items]
Agregate purchase commitment	$ 0.9

Leases (Schedule of ROU Assets and Lease Liabilities) (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
ROU Assets:
Operating	$ 1,814,396	$ 2,082,300
Financing	90,467	449,628
Total ROU assets	1,904,863	2,531,928
Current:
Operating	459,792	964,434
Finance	43,150	266,470
Noncurrent:
Operating	2,977,402	1,492,544
Finance	3,644	46,794
Total lease liabilities	$ 3,483,988	$ 2,770,242

Leases (Schedule of Maturities of Lease Liabilities) (Details)	Dec. 31, 2021 USD ($)
Operating
2022	$ 745,850
2023	639,172
2024	648,767
2025	544,080
2026	378,279
Thereafter	2,126,371
Total lease payments	5,082,519
Less: Interest	(1,645,325)
Present value of lease liabilities	3,437,194
Finance
2022	44,850
2023	3,364
2024	280
2025
2026
Thereafter
Total lease payments	48,494
Less: Interest	(1,700)
Present value of lease liabilities	46,794
Total
2022	790,700
2023	642,536
2024	649,047
2025	544,080
2026	378,279
Thereafter	2,126,371
Total lease payments	5,131,013
Less: Interest	(1,647,025)
Present value of lease liabilities	$ 3,483,988

Leases (Schedule of Statement of Operations Classification of Lease Costs) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lease Cost
Total lease costs	$ 1,430,238	$ 1,771,760
Operating Expense [Member]
Lease Cost
Operating	1,055,595	1,205,551
Amortization	359,162	508,962
Other Expense [Member]
Lease Cost
Interest expense	$ 15,481	$ 57,247

Leases (Schedule of Other Information) (Details)	Dec. 31, 2021
Weighted average remaining lease term (in years)
Operating leases	7 years 7 months 6 days
Finance leases	10 months 24 days
Weighted average discount rate:
Operating leases	8.90%
Finance leases	9.10%

Leases (Schedule of Supplemental Cash Flow Information) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash used in operating activities
Operating leases	$ 1,055,595	$ 1,205,551
Finance leases	15,481	57,247
Cash used in financing activities
Finance leases	266,470	579,029
ROU assets obtained in exchange for lease obligations
Operating leases	615,761	1,008,039
Finance leases

License agreements, research collaborations and development agreements (Details) - USD ($)	1 Months Ended	10 Months Ended	12 Months Ended
	Apr. 30, 2021	Jul. 13, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Apr. 30, 2020
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract			$ 4,306,031	$ 4,214,441
Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract			$ 836,152	1,342,341
FISH License [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Termination date of agreement			Oct. 30, 2020
Exit date of agreement			Jun. 30, 2021
Royalty expense			$ 11,721	(68,854)
Settlement fee			$ 350,000
Royalty percentage on sale of products			10.00%
New York State Department of Health and ILUM Health Solutions, LLC [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Collaboration revenue receivable over 15 months of the project			$ 1,600,000
Contractual agreement period			15 months
Extended term of collaboration agreement	6 months
Termination date of agreement	Sep. 30, 2021
New York State Department of Health and ILUM Health Solutions, LLC [Member] \| Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract			$ 558,000	388,000
OpGen [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Contract value	$ 540,000					$ 450,000
Sandoz [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Contractual agreement period			36 months
Termination date of agreement			Jan. 31, 2025
Qiagen [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Contractual agreement period			20 years
Global leading IVD corporation [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Contractual agreement period			10 months
Termination date of agreement			Jul. 13, 2020
Revenue from contract		$ 1,200,000	$ 0	870,000
Option fees received					$ 550,000
Siemens [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Royalty expense			$ 146,375	$ 2,775
Siemens [Member] \| Minimum [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Royalty rate			1.30%
Siemens [Member] \| Maximum [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Royalty rate			40.00%